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INTRODUCTION 
The amyloidogenic processing of the membrane-associated amyloid precursor protein (APP), 
regulated by calcium signaling pathways, results in the formation of the neurotoxic p-amyloid 
peptide (PAP), that is the major component of senile plaques in Alzheimer's disease (AD). pAP-
induced cytotoxicity involves disruption of resting intracellular free calcium level ([Ca2+]i). Certain 
agents used in the treatment of co-morbid conditions in AD, such as haloperidol (HAL), have been 
shown to interact with calcium homeostasis and PAP formation. Toxic effects of PAP are 
ubiquitously present in the body, however its pathomechanism is difficult to be examined in the 
central nervous system. A substantial body of data exists indicating that biochemical changes of 
brain cells in various neurobiological diseases with systemic manifestation (eg. AD) are reflected in 
peripheral tissues, such as in fibroblasts and lymphocytes. 
OBJECTIVES OF THE STUDY 
In order to investigate calcium and other factors (ie. genes) involved in PAP toxicity and APP 
processing, the present study focuses on calcium homeostasis in the periphery, also on APP 
metabolism and gene expression profile in the brain. The effect of certain antipsychotics, including 
HAL and risperidone (RISP), is also evaluated for their effects on pAP-induced calcium-imbalance 
and their role on APP metabolism and gene expression. 
EXPERIMENTAL PROCEDURES 
Resting intracellular calcium levels were assessed by fluorescence ratio imaging of the calcium 
indicator dye Fura-2AM (FL340/380) in human fibroblasts and lymphocytes. Rat cortical APP levels 
after acute and chronic intra-peritoneal treatment of rodents with HAL or RISP were determined 
using Western-immunoblot techniques. Cortical gene expression was analyzed by cDNA 
microarrays after the same treatment modalities. Results were confirmed by real-time quantitative 
reverse transcription polimerase chain-reaction (QRT-PCR). 
RESULTS 
1. Calcium homeostasis. FL340/380 of control lymphocytes was 1,001±0.117, whereas Alzheimer 
lymphocytes exhibited a ratio of 1.131±0.100. In contrast, FL340/380 of control fibroblastic 
cultures revealed 2.48±0.162, and Alzheimer fibroblasts exhibited 2.052±0.207 FL340/380-
Exposure of both control lymphocytes and fibroblasts to PAP for 2 and 16 hours, respectively, 
caused a rise in the free cell calcium (FL340/380: 1.507±0.368 and 2.666±0.08, respectively). 
Alzheimer lymphocytes and fibroblasts showed a FL340/380 of 1.130±0.075 and 2.055±0.125, 
respectively after PAP treatment. Chronically, FL340/380 was initially elevated in fibroblastic 
cultures, but after 16-weeks FL340/380 gradually fell below resting levels. Co-incubation of 
HAL or RISP with PAP resulted in no significant alteration in the resting calcium levels of 
fibroblasts. 
FL34WJ80 of lymphocytes 
Comparative fluorimetric measurements on lymphocytes of human Alzheimer and control 
donors on FL340/38o using Fura-2AM. Resting [Ca2+], appeared to be higher in AD cells 
when compared to that seen with control lymphocytes. After incubating cells in the 
presence of pAP, the [Ca2+]i of the control cells elevated, while that of AD lymphocytes did 
not differ considerably. (*P<0.05) 
Samples FC34Ü/3HÜ Number of 
(mean±SD) cuvettes 
Control 1.001±0.117 23 
Alzheimer 1.131±0.100* 18 
Control+ßAP 1.507±0.368* 23 
Alzheimer+ßAP 1.130±0.075 18 
FLJ4W38O of fibroblasts: treatment with HAL and RISP 
Comparative fluorimetric studies on human control and Alzheimer fibroblasts on FL^Q^O 
utilizing the Ca2+-indicator dye Fura-2AM. Cells were cultured with or without |3AP and/or 
HAL/RISP for 16 hours at 37°C. Elevation in FL340«8o after pAP-trcatment was attenuated 
by co-administration of HAL or RISP. (*P<0.05, when Alzheimer samples are compared to 
the controls, and **P<0.05, when samples are compared to their untreated counterparts 
only) 
Cultures FL340/380 Number of 
(mean±SD) coverslips 
Control 2.48±0.162 16 
Alzheimer 2.052±0.207* 42 
ControI+pAP 2.666±0.08** 16 
AIzheimer+pAP 2.055±0.125* 42 
Control+HAL 2.41±0.119 16 
Alzheimer+HAL 2.049±0.202* 16 
Control+pAP+HAL 2.46±0.123 16 
Alzheimer+PAP+HAL 2.054±0.198* 16 
Control+RISP 2.479±0.200 16 
Alzheimer+RISP 2.054±0.172 16 
Control+pAP+RISP 2.482±0.114 16 
Alzheimer+pAP+RISP 2.053L0.099 16 
Time-course of pAP on [Ca2+]f of human fibroblasts 
Short-term exposition of fibroblasts to pAP results in an increased [Ca2+]j. The rise in the 
calcium-level peaks after an approximately half-a-week treatment with the peptide. The 
flow-chart demonstrates that the reversible elevation of [Ca2+], turns into a fall at around the 
16th week of exposition to pAP, and yields a sustained decrease in the [Ca2+L Calcium-
level of control cultures with no PAP treatment appeared to be unchanged during the 
experiment. 
Fibroblast with pAP - - Fibroblast without |3AP 
Days 
APP-levels. Significant rises in the relative values of rat cortical APP levels were between 2-
6% when compared to that seen with control levels after 12-96 hours of treatment with HAL. 
Neither chronic HAL, nor acute or chronic RISP treatment has resulted in altered APP 
concentration. 
Time-course of HAL on rat cortical APP concentrations 
Intraperitoneal administration of HAL resulted in significant increase in rat cortical APP-
level in therapeutic dose within 24 hours. This elevation was seen even in 12 hours in toxic 
dose of the drug. Both therapeutic and toxic HAL leaved APP concentrations unchanged on 
the long-run. (*P<0.05) 
- - Control Therapeutic dose Toxic dose 
time 
Time-course of RISP on rat cortical APP concentrations 
The flow-chart delineates the effect of the typical antipsychotic drug on the APP 
metabolism in an acute or chronic time-frame. RISP did not significantly interfere with the 
APP-levels either in therapeutic or toxic doses. 
Control Therapeutic dose Toxic dose 
time 
3. Gene expression profile. HAL significantly over-expressed 8 and repressed 6 genes, whereas 
RISP induced the expression of 7 and down-regulated 27 genes in a cDNA microarray system 
containing 8,000 clones. QRT-PCR results were in accordance with the expression of these 
genes, and therefore the semi-qualitative results of cDNA-micro-chips were validated. 
Of the significantly altered transcripts, only genes involved in AD or directly linked to this 
thesis (ie. ionic homeostasis and protein metabolism), and those with a A Fold > 2.00 are 
listed in the following tables. 
List of differentially expressed genes in rat fronto-temporo-parietal cortex after acute 
(96 hours) treatment with HAL. A: over-expressed, and B: repressed genes 
A: 
Clone name A Fold Accession Functional 
(mRNA) (mean) number group 
Rattus nor\>egicus cDNA clone, similar 
to Human B12 protein mRNA 1.96 AA900186 
Ion transport 
S100 calcium-binding protein A8 
(calgranulin A) (S100A8) 1.41 NM 053822 
Ion transport 
Glutamate receptor subunit GluR2-flip 
mRNA. complete cds 1.22 AF164344 
Ion transport 
Calmodulin 2, mRNA, complete cds 1.13 BC058485 Ion transport 
Rattus norvegicus APP770 mRNA, 
complete cds 1.76 AF513015 
Other 
B: 
Clone name A Fold Accession Functional 
(mRNA) (mean) number group 
Circadian 
Serotonin N-acetyltransferase -2.15 NM 012818 rhythm 
Inwardly rectifying K+-channel -1.89 D61687 Ion transport 
Voltage-dependent calcium channel y-7 
subunit (Cacng7) mRNA, 
complete cds -1.21 AF361349 
Ion transport 
Tyrosine aminotransferase -2.68 NM 012668 Metabolism 
Disintegrin and metalloprotease domain 
2 -2.15 NM 020077 
Protein 
metabolism 
Type I pro-a; collagen-like sequence -3.25 AF050214 Other 
TPCR09 protein -2.07 X89698 Other 
List of differentially expressed genes in rat fronto-temporo-parietal cortex after 
chronic (4 weeks) treatment with HAL 
Clone name A Fold Accession Functional 
(mRNA) (mean) number group 
K+-channel (erg2) 1.11 AF016192 Ion transport 
List of significantly A: induced, and B: down-regulated genes in rat fronto-temporo-
parietal cortex after acute (96 hours) treatment with RISP 
A: 
Clone name A Fold Accession Functional 
(mRNA) (mean) number group 
Plakoglobin 2.20 U58858 Cell adhesion 
RING finger protein 2.07 AF036255 Development 
Immune 
Small inducible cytokine subfamily A20 2.31 NM 019233 response 
Protein 
RAB15 2.24 M83679 metabolism 
Protein 
nL-tvrosine kinase-related protein 2.67 AB073721 metabolism 
Protein 
CLN2 tripeptidyl peptidase I 2.35 AB043870 metabolism 
K*-channel (erg2) 2.08 AF016192 Ion transport 
Na+-channel. voltage-gated, tvpe 10a 1.01 NM 017247 Ion transport 
Vacuolar adenosine triphosphatase-P 1.40 Y12635 Ion transport 
ATPase, Na+/K+ transporting, a, 2.00 NM 012504 Ion transport 
Acyl-Coenzvme A dehvdrogenase, C-4-
12 2.13 NM 016986 
Metabolism 
Activating transcription factor 3 2.50 NM 012912 
Transcription 
regulator 
SH-PTP2 protein tyrosine phosphatase 
11 2.74 NM 013088 
Signal 
transduction 
Interleukin 6 reccptor 3.12 NM 017020 
Signal 
transduction 
Endothelin receptor 2.04 NM 017333 
Signal 
transduction 
Integrin-binding sialoprotein 2.14 NM 012587 Others 
Neurexin Ilia (axon guidance) 2.84 L14851 Others 
B: 
Clone name A Fold Accession Functional 
(mRNA) (mean) number group 
CD5 -2.60 X78985 Cell adhesion 
Activity regulated cytoskeletal-
associated protein -2.31 NM 019361 
Development 
Immune 
Protein phosphatase 1, regulatory 14a -2.61 NM 130403 response 
Disintegrin and metalloproteasc domain 
2 -2.15 NM 020077 
Protein 
metabolism 
Voltage-dependent calcium channel g8 -2.21 NM 080696 Ion transport 
Plasma membrane CA2+-ATPase 3 -1.47 M96626 Ion transport 
Inwardly rectifying K+-channel -2.32 D61687 Ion transport 
y-glutamvlcvsteine synthetase -2.12 NM 017305 Metabolism 
Interleukin 10 receptor-a -2.68 NM 057193 
Signal 
transduction 
Basignin (0x47 antigen or CE-9) -2.02 NM 012783 
Signal 
transduction 
Soluble adenvlyl cyclase (SAC) -2.37 AF081941 Transport 
Type I pro-a2 collagen-like sequence -3.77 AF050214 Others 
Putative zinc-finger protein -3.40 AJ007467 Others 
U2 RNA 3' end -2.63 M10882 Others 
Glucagon (Gcg) -2.17 NM 012707 Others 
List of significantly A: up-regulated, and B: repressed genes in rat fronto-temporo-
parietal cortex after chronic (4 weeks) treatment with RISP 
A: 
Clone name A Fold Accession Functional 
(mRNA) (mean) number group 
Immune 
Protein phosphatase 1, regulatory 14a 2.30 NM 130403 response 
Receptor activity modifying protein 2 3.35 AB042888 
Signal 
transduction 
B: 
Clone name A Fold Accession Functional 
(mRNA) (mean) number group 
Inwardly rectifying K"-channel -1.65 D61687 Ion transport 
Uncoupling protein 2, mitochondrial -1.25 NM 019354 Ion transport 
Other than the above transcripts, a number of genes involved in metabolism in general (eg. 
glutathione S-transferase), cell cycle (eg. growth accentuating protein 43), adhesion (eg. integrin 
Pi), immune response (eg. T-cell receptor a-chain), and others (eg. FSH-regulated protein) were 
also differentially expressed. 
DISCUSSION 
1. Calcium homeostasis. Alzheimer lymphocytes maintain increased, whereas Alzheimer 
fibroblasts show decreased resting intracellular calcium levels when compared to their 
respective control counterparts. Exposure to PAP results in elevated calcium concentration in 
control samples, however both Alzheimer lymphocytes and fibroblasts appeared to be 
refractive to PAP. On the long-run, PAP had a time-dependent biphasic-effect by initially 
increasing calcium-levels, but chronically antagonizing it in control fibroblastic cultures. This 
novel finding, and the fact that lymphocytic turnover is higher than that of fibroblasts, give an 
explanation between the differential resting calcium levels in the cell-types studied. Both HAL 
and RISP have proved to efficiently antagonize pAP-induced calcium imbalance in fibroblasts 
without directly interfering with calcium homeostasis. 
2. APP-levels. The levels of APP have been significantly increased after acute HAL treatment 
only in both therapeutic and toxic doses. Chronic administration of HAL and treatment with 
RISP in general had no impact on APP metabolism. By being a calcium-antagonist, HAL may 
prevent APP-processing from shifting to the amyloidogenic pathway, therefore it prevents 
PAP formation and, in turn, precludes calcium imbalance in a process that might be referred to 
as "protective cycle." 
3. Gene expression profile. The expression of several genes was interfered with in this study in 
a similar manner by HAL and RISP. Members of signal transduction, structural elements, 
factors related to protein metabolism in general, components involved in cell survival, 
determinants of membrane conductance and ion transport, and basics of nuclear functions, 
were some of the genes with altered expression. 
CONCLUSIONS 
1. Fibroblasts and lymphocytes show biochemical differences in AD by exhibiting abnormal 
at* homeostasis. 
2. Biphasic effect of fiAP may shed new light on understanding cellular alterations in dementia 
and differences between tissue-specific pathologies in the same condition. 
3. Biochemical alterations in the periphery may support the diagnosis of AD, may help 
monitoring the progression of the disease and responsiveness to treatments. 
4. HAL and RISP are potent in antagonizing fiAP-induced Co2*-imbalance. 
5. These antipsychotics are safe with respect to APP metabolism, and acute HAL (ie. pulse-
therapy) might be beneficial on APP processing in AD. 
6. A "protective cycle" of antipsychotics is proposed in AD. 
7. HAL and RISP are involved in interfering with the expression of a large array of genes 
involved in Co2 -signaling, survival and cellular plasticity. 
8. Antipsychotics with different pharmacological characteristics share targets at the molecular 
level, including Co2*-homeostasis. 
9. CO2* is central in the pathogenesis of AD, and agents targeting Ca2* may slow or inhibit the 
progression of and might even reverse AD and its corollary symptoms. 
10. Ca2+ might be a unifying molecule in most neurodegenerative disorders and also in metabolic 
diseases afflicting extraneuronal organs. 
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INTRODUCTION 
Clinical aspects of Alzheimer's disease 
Each year millions of people go through a stage of mental deterioration in which their ability to 
remember gradually fades. At certain stages of the disease a simple task that is taken for granted, 
such as how to make a phone call, becomes insurmountable. Most of the people who are afflicted 
with this illness are elderly, but their symptoms are not caused by their aging. After three to ten 
years from the onset of the disease the patients become unable to recognize close relatives. 
Eventually fading remembrances slowly destroy their emotional balance, their sense of judgment, 
and their personal identity. Due to their inability to support themselves they gradually become 
bedridden. Complications arising from this vegetative state ultimately lead to death. 
In the early 1900's the symptoms of this disorder were recognized by a German psychiatrist, Alois 
Alzheimer, for whom this disease is named1. Scientists have recently made major advances in 
understanding the mechanism which triggers the illness. The ultimate goal of Alzheimer research is 
to elucidate the pathway underlying the massive neuronal death seen in the brain with this 
syndrome leading to this specific kind of dementia - a condition denoting a progressive decline in 
mental function, in memory, and in acquired intellectual skills. About 70% of dementia cases are 
due to Alzheimer's disease (AD). 
AD is a major public health problem secondary to the increased life expectancy of the general 
population and a better appreciation of the socio-economic consequences of the disease. AD is a 
disease with several million living victims worldwide2. With an annual incidence of about more 
than half a million cases, and given the aging of the population, improvements in life expectancy, 
and in treatment of AD, the prevalence of this condition will quadruple in the next 50 years . 
A definitive diagnosis of this disorder requires pathological examination of the brain, but diagnosis 
on clinical grounds according to the Diagnostic and Statistical Manual of Mental Disorders, 4th 
Edition (DSM-IV) criteria3 alone is correct in the majority of cases, especially if other causes have 
been ruled out. Neuropathological examination from autopsy studies suggests a 90% accuracy rate 
in the clinical detection of AD4. 
Computerized tomographic (CT) and magnetic resonance imaging (MRI) of the brain of Alzheimer 
patients show thin cortical gyri of the postero-temporal and postero-parietal lobes (ie. brain 
atrophy), enlarged (lateral) ventricles, and atrophy of the hippocampus. These findings are not 
specific, however, since other conditions may also produce atrophy of the brain. Furthermore, there 
is some degree of atrophy in normal aging5'6. 
Dementia in AD steadily worsens, with a loss of 3 to 4 points per year on a standard assessment 
instrument such as the Mini-Mental State Examination (MMSE)7. Various patterns of deficits are 
seen, with the most common being an insidious onset, with recent memory loss followed by the 
development of aphasia, apraxia, and agnosia after several years. Some patients present with 
irritability and personality changes in the early stages. Later during the course of the disease, 
patients usually develop gait and motor disturbances, eventually becoming mute and bedfast. On 
average, AD patients live for 8 to 10 years after they are diagnosed, although the disease can last for 
up to 20 years8. 
In addition to debilitating the patient, AD impacts on families. This impact is emotional, with 
caregivers experiencing depression, guilt, anger, and physical stress leading to caregiver frailty, as 
well as economic consequences, with costs of care in the tens of thousands of dollars per year9'10. 
l 
Histopathological findings in AD 
The formation of senile plaques in the brain is a main pathological feature of AD. These plaques 
contain deposits of a 38-43-amino-acid protein-residue, called the P-amyloid peptide (PAP)1 . In the 
presence of senile plaques neurites (ie. neuronal processes: the dendrites and axons) degenerate; 
ultimately brain cells necrotize. The dystrophic neurites and cells surround the senile plaques and 
together they are referred to as the neuritic plaques12. This morphological characteristic has led to 
the speculation that the amyloid masses, particularly the presence of PAP in the extracellular space 
cause the death of adjacent neurons. 
Apart from forming the senile plaques, P-amyloid fibrils are deposited along the walls of the 
cerebral and meningeal vascular system, too, causing vascular amyloid angiopathy13. 
Another microscopic hallmark of AD is the profound neurodegeneration in the frontal, temporal and 
parietal cortices. A variety of neurochemical deficits affect the serotonergic, noradrenergic, and 
cholinergic systems14. The cholinergic deficit of AD is well documented; there is a marked loss of 
neurons in the basal forebrain nuclei (particularly in the Mevnert's nucleus) that usually exceeds 
75% of the total neuronal population at the time of an autopsy 5. 
Cytopathological manifestation of AD is the presence of paired helical filaments (PHF) within the 
brain cells16. These intraneuronal filaments aggregate and form neurofibrillary tangles (NFT)17. 
This amorphous material is assembled from an abnormally phosphorylated and transformed 
cytoskeletal protein called tau (T)18. Normally, tau plays an important role in stabilizing 
microtubules and thus helps to maintain neural vesicular transport. The most conspicuous effect of 
the phosphorylation of tau is the decrease in its binding capacity to the microtubules. This causes a 
loss of axonal transport, since microtubules provide the tracks for vesicle traffic driven by motor 
proteins. 
P-amyloid peptide 
PAP is derived from the highly regulated and sequential cleavage of amyloid precursor protein 
(APP) as a normal physiological product19,20. It is a soluble component at nanomolar concentrations 
of the plasma and the human cerebrospinal fluid (CSF)21 as a range of isoforms between 38 and 43 
amino acids in length. 
The presence of pAP under normal conditions suggests the possibility of a physiological role for 
PAP. PAP may serve an essential role in synapse and synaptic plasticity that underlie learning and 
memory22,23. A role for PAP in neural and synaptic structure-functional plasticity is additionally 
supported by an increase of synaptic APP with learning capacity24, by neuronal activity dependent 
secretion of natural PAP25, and up-regulating a synaptic vesicle protein transcript by pAPi^' . 
Because soluble PAP is apparently a physiological peptide, it was proposed that the key to the 
cellular toxicity of pAP appears to be proportional to its aggregation state27. The aggregation of 
soluble PAP peptide into fibrillar cross-P pleated-sheet conformation to form oligomers, polymers 
or protease-resistant fibrils over time is generally considered to be a critical event in the pathology 
of AD28. This is signified by the finding that the predominant carboxyl-terminal isoforms in CSF of 
healthy individuals are pAPM0 (90%) and the fibrillogenic PAPM2 (10%). In patients with AD, 
however, the relative proportions of 1-40 and 1-42 change to -50% each29. Moreover, PAPM2 is the 
major component of amyloid deposits in brain with AD . 
Interestingly, PAP deposition has been observed in various brain areas without accompanying 
neurodegeneration31,32^3, whereas neurodegeneration can occur in areas with no PAP deposition. 
Therefore, attention is turning away from the deposits of extracellular insoluble aggregated amyloid 
2 
in plaques and toward soluble, oligomeric and even intracellular PAP35'36. Accumulation of 
intracellular PAP (PAPi) and preamyloid protrofibrils are being recognized as a contributing factor 
or initiating event towards neuronal death and synaptic loss in early AD pathogenesis37. 
The theory that PAP plays a key role in neurodegeneration in AD has been proven both in vivo and 
in vitro39'39'40, leading to the "amyloid cascade" hypothesis41,42. The neurotoxicity exerted by 
aggregated PAP can be mediated by several mechanisms. 
Several reports suggest that the neurotoxic effects of PAP are mediated by the disruption of calcium 
homeostasis, resulting in increased neuronal intracellular calcium levels ([Ca2+]i)43,44. PAP is a 
potent L-type voltage-gated calcium-channel activator45, and causes reduction in the activity of 
Na+/K+-ATPase46, Na+/Ca2+ exchanger47 and K+-channel48. pAP is also proved to directly form non-
selective calcium-channels49. Neurons exposed to pAP exhibit calcium responses sensitive to 
excitatory amino acids and membrane depolarization: enhancement of glutamate-mediated 
excitotoxicity50 adds to the elevated calcium-levels. 
When in an aggregating form, PAP induces membrane lipid peroxidation by generating reactive 
oxygen species 1,52,S3. The increased ROS and intracellular calcium levels induced by PAP impair 
mitochondrial function and can trigger a programmed cell death process called apoptosis54,55,56. 
Early association of activated microglial cells and reactive astrocytes in neuritic plaques and the 
appearance of inflammatory markers indicate a state of chronic inflammation in AD. Immune 
activation and/or inflammatory activity have been shown to be significantly elevated in the brains of 
AD patients57. Microglia and astrocytes would be activated, perceiving PAP oligomers and fibrils as 
a foreign material, because these kinds of PAP assemblies are apparently never observed during 
brain development and in the immature nervous system58. pAP also directly activates the 
complement system59. The importance of the inflammatory component to the disease mechanism is 
supported by the consistent finding that anti-inflammatory drugs have a beneficial effect on disease 
progression. 
Extracellular interaction of P-amyloid aggregates with cell membranes could induce a wide variety 
of alterations through numerous potential target sites that are consistent with the pathological 
activation of signal transduction. These include the mitogen-activated protein kinase (MAPK), 
calpain, cyclin-dependent kinase-5 (cdk-5), glycogen synthase kinase-3P (GSK-3P), and tyrosin 
kinase Src pathways60'61; by progressive and sustained activation thereof, PAP induces tyrosine 
phosphorylation of numerous neuronal proteins, including tau and microtubule-associated protein-
2c (MAP-2c)62. 
The calcium theoiy in AD 
Calcium plays fundamental roles in the development, function, and plasticity of nerve cell circuits63. 
The regulation of Ca2+ dynamics in neurons is very complex, involving proteins localized in 
essentially all major subcellular structures including the plasma membrane, cytosol, mitochondria, 
and endoplasmic reticulum64. The concentration of Ca2+ outside the cell (1-2 mM) is 10,000-fold 
higher than in the cytosol (50-200 nM), and this concentration gradient is maintained largely by 
removal of Ca2+ from the cytoplasm by plasma membrane and endoplasmic reticulum (ER) Ca2+-
ATPases. 
Pathophysiologically, interfering with the intracellular ionic homeostasis of neurons is thought to be 
one of the most conspicuous brain cell destroying activities of PAP43. Destabilization of Ca2+ 
homeostasis in neurons plays a central role in AD pathogenesis44. In the presence of the peptide, the 
intracellular calcium concentration of cells has been reported to increase through various, but not 
fully understood mechanisms, including the putative calcium channel activity of PAP49, or its 
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interaction with membrane structures. Measurements of calcium concentrations in brain tissue from 
AD patients reveals evidence for increased overall levels (free and protein-bound) of calcium65. 
Levels of activated calcium-dependent enzymes and proteases are also increased66. 
Increase in the calcium concentration due to PAP is balanced by pumping out the excess. This 
feature expends a large amount of the cells' energy, preventing them from providing for their own 
physiological and biochemical pathways any longer. Concentration of ROS will then increase 
which may further damage cells. The effects disable cells to control their fluid and ion balance. 
Water and charged particles (especially even more Ca2+) that are normally pumped out now stream 
in. Additionally, alterations in intracellular Ca2+-levels are known to induce cell loss by apoptosis, a 
degenerative pathway typically associated with gene-directed cellular suicide termed programmed 
cell death. Neurons that are meant to last a lifetime can be transformed at an early stage to this form 
of death. 
p-amyloid-precursor-protein 
P-amyloid peptide derives from the proteolytic processing of its precursor, the P-amyloid-precursor-
protein (APP)67. Full-length APPs are considered integral membrane glycoproteins containing a 
large extracytoplasmic domain, a transmembrane region, and a small cytoplasmic sequence68. The 
APP spans the cell membrane between amino acids 700-723. The P-amyloid site is represented by 
the amino acids 672-713; that is, the C-terminal of PAP takes part in forming the transmembrane 
region. 
In mammals, the APP protein is expressed ubiquitously in all tissues examined including neurons, 
glias, and non-neuronal cells69'70, including fibroblasts but there are differences in the expression 
levels of the splicing variants. Alternative splicing of the APP gene gives rise to at least 10 protein 
isoforms. Three of them known to contain PAP are APP770 (frill-length APP), APP751 (minus exon 
8) and APP695 (minus exons 7 and 8). Exon 7 encodes the Kunitz protease inhibitor (KPI)72; KPI-
containing APP isoforms are more amyloidogenic73. Neuronal cells predominantly express APP695, 
whereas the APP751/770 form is mainly expressed in non-neuronal tissues such as heart, lung, liver, 
kidney, muscle and spleen74'75. In the brain, APP is expressed with high levels in the hippocampal 
formation76. 
a-secretion 
APP can undergo at least two post-translational processing pathways. In the non-amyloidogenic or 
normal pathway, constitutively secreted APP (referred to as sAPPa), lacking the transmembrane 
and cytoplasmic sequences, is produced after full-length molecules are cleaved by an enzyme called 
a-secretase between amino acids Lysi6 and Leun of the P-amyloid sequence77 (between the amino 
acid 687-688 of the full-length precursor protein). Because sAPPa is produced after full-length 
molecules are cleaved by the a-secretase within the P-amyloid sequence, this cleavage event is 
incompatible with the production of the neurotoxic P-amyloid (Figures 1,2). 
sAPPa has several neuroprotective properties. sAPPa protects neurons from ischemic injury78'79, 
has effects on ion fluxes8, stimulates neurite outgrowth81, promotes proliferation82, cell survival83, 
and protects neurons from oxidative, excitotoxic and metabolic, including PAP85-induced insults. 
Regarding signal transudation pathways, sAPPa is implicated to play a role in activation of 
neuroprotective NF-xB-dependent transcription86, phospholipase C - protein kinase C (PKC) and 
inositol trisphosphate (IP3) pathways. 
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Figure 1: Amino acid sequence of APP in the pAP region 
Sites of proteolytic cleavage by a-, P-, and y-secretases are shown. Mutations in APP which cause familial forms of AD or a related amyloidosis are also presented. PAP region 
within the precursor protein is highlighted. 
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Figure 2: Schematic diagram of APP and its principle metabolic derivatives 
The figure depicts the largest of the known APP alternate transcripts, comprising 770 amino acids. Regions of interest are indicated at their correct relative positions. A single 
membrane-spanning domain at amino acids 700-723 is indicated by the horizontal hatched bars. The PAP fragment (red box) includes 28 residues just outside the membrane plus the 
first 11-15 residues of the transmembrane domain. The left lower diagram indicates the site of the constitutive proteolytic cleavage that enables secretion of the soluble ectodomain 
of APP (sAPPa) and retention of the 83-residue C-terminal fragment (~10kDa) in the membrane (CTFa). This non-amyloidogenic processing of APP by a-secretase precludes pAP-
formation. The right lower portion of the diagram depicts the alternative proteolytic cleavage by P-secretases that results in the formation of sAPPp (an ectodomain similar to 
sAPPa), and a potentially neurotoxic ~12kDa C-terminal fragment (CTFP), which serves as an intermediate in the generation of PAP. A subsequent y-cleavage after the a- or P-
secretion yields non-toxic p3 and neurotoxic PAP, respectively. As a by-product of the y-activity, non-toxic CTFy is formed, which is subject to e-cleavage. 
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P-secretion 
PAP is derived from the highly regulated and sequential cleavage of APP by proteases designated (3-
secretase and y-secretase. This amyloidogenic P-secretion pathway is an alternative of normal APP 
processing, involving cleavage of APP by P-secretase adjacent to the N-terminal residues of the 
PAP sequence, p-secretase generates the N-terminus of PAP, cleaving APP to produce a soluble 
version of the precursor (sAPPP) and a 99-amino-acid residue C-terminal fragment that remains 
membrane bound (CTF99, or CTFP). 
y-secretion 
Cleavage after P-secretion by a subsequent y-secretase at position 40,42 or 43 of the PAP sequence 
within CTFP results in the release of neurotoxic PAP, a 4kDa derivative from APP88, and a 
remaining 57-59 residue C-terminal tail: CTFy (Figure 2). In addition, cleavage of the by-product of 
a-secretion, CTF83 (CTFa) by y-secretase yields non-pathogenic derivative referred to as p3 and 
CTFy. In contrast with a-secretion that almost exclusively occurs in the plasma membrane, APP 
may be internalized and processed in the endosomes (proteasomes/lysosomes) during sequential 
p/y-secretion to produce PAP. 
y-activity is heterogeneous: most of the full-length PAP species produced is a 40-residue peptide 
(PAP 1^0), whereas a small proportion is 42-43-residue C-terminal variant (PAPj-42/43)- The longer 
and more hydrophobic PAP 1.42/43's are much more prone to fibril formation than is PAPMO89, and 
even though PAP 1.42 is a minor form of PAP, it is the major PAP species found in cerebral 
plaques90. Moreover, y-secretase has remarkably loose sequence specificity for its substrate because 
many mutations in APP near the y-secretase site still allow PAP production. 
Identifying y-activity revealed that y-secretase is a multimeric entity: presenilins (PS), nicastrin, 
Aphl and Pen2 generate an active y-secretase complex. 
Presenilins (PSs) may be the active center of y-activity. y-secretase has been demonstrated to have 
an acidic pH optimum, consistent with the notion that the presenilins are intramembranous aspartyl 
proteases . Also, PSs are chaperoning molecules that may bring APP to the proximity of y-
secretase. 
The missense mutations in the gene encoding APP, as well as those in the genes encoding PS1 and 
PS2, share the common feature that they alter the y-secretase cleavage of APP to increase the 
production of the amyloidogenic PAPm2 • 
Behavioral and psychological symptoms of dementia (BPSD) 
AD is characterized clinically by decline in memory and cognitive functions, however 
manifestations of BPSD, including psychosis, delusions, hallucinations, agitation, etc. during the 
course of the disease are significant events4"7. Their frequency ranges from 50 to 90% and they can 
occur at any point in the disease process, often being the presenting symptom. The number and 
severity of behavioral problems increase with worsening of cognitive impairment93. BPSD can be 
mainly grouped into behavioral and psychological symptoms of dementia disorders. The former are 
usually identified on the basis of patient observations, while the latter are mainly assessed on the 
basis of interviews with patients and relatives94. 
Interestingly, AD pathology is infrequent in patients with schizophrenia (SCH)95'96. It has been 
proposed that medications used to treat SCH, such as haloperidol (HAL), might have a protective 
effect against developing AD neuropathology, which would account for a low frequency of these 
changes in elderly SCH. The mechanism by which antipsychotic drugs might exert such an effect is 
not known. 
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A systemic approach to neurometabolic disorders 
P-amyloid is reported to be ubiquitously present in the body97, and has every now and then been 
demonstrated to form depositions in the skin of Alzheimer patients98, presumably interfering with 
intracellular biochemical pathways of peripheral tissues. Indeed, several alterations in the blood of 
AD patients have been reported. In lymphocytes, changes in ionic and signal transduction 
pathways99, elevated number of apoptotic peripheral mononuclear cells100, increased vulnerability to 
programmed cell death101 and raised levels of oxidative DNA damage102 was reported. With respect 
to platelets, disrupted membrane fluidity103'104, hypofunction of mitochondrial enzymes105, and 
modified activation of cells106 have been found. Dysfunctions of red blood cells including decreased 
erythrocyte AchE activity are also observed . In case of fibroblasts, disturbances of Ca -
uptake1 , ionic homeostasis109, glucose metabolism110, proteolysis111, signal transduction112 and 
DNA repair113 are some of the biochemical changes reported in AD. 
Apart from brain-specific changes, abnormalities attributed to AD seen in many peripheral cell 
types such as erythrocytes, lymphocytes, platelets and fibroblasts have lead to the speculation that 
AD might be a systemic disorder, with the most prominent pathology in the cognitive functions of 
the CNS. 
A substantial body of data exists indicating that biochemical changes of brain cells in various 
neurobiological diseases with systemic manifestation are reflected in peripheral tissues, such as 
fibroblasts and lymphocytes114'115. In the course of surveying a wide variety of these mirror 
changes, previous reports have proved that fibroblasts and lymphocytes can serve as models and 
diagnostic markers of several neurodegenerative disorders, including metachromatic 
leucodystrophy, Tangier's disease, and generalized glycogenosis114'116. 
Lymphocytes and cultured fibroblasts offer many advantages for the study of various 
pathobiochemical alterations in AD. These pathways are more robust in these living cells than in 
postmortem material, such as brain, and the results are not complicated by agonal or postmortem 
events117. 
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OBJECTIVES OF THE STUDY 
1. Involvement of the periphery in AD 
The identification of the mirror shifts in AD described in the introduction has been of my 
interest. The aim was to study whether readily available tissues such as fibroblasts and 
lymphocytes may serve as simple supportive systems to monitoring intracellular ionic 
imbalance, particularly that of the basal intracellular free calcium levels ([Ca2 4]j) in AD. Broadly 
in line with this hypothesis, the present communication summarizes techniques which have been 
used to study the biochemistry and physiology of skin fibroblasts and lymphocytes isolated from 
patients with certain neurometabolic disorders including AD. Consistent with this, alterations in 
calcium homeostasis of fibroblasts and lymphocytes associated with AD are discussed in the 
present thesis. 
2. Pharmacological studies 
Several investigators have found a low frequency of AD in patients with SCH, and it has been 
proposed that antipsychotic medications may be responsible9 . 
The prototype classical antipsychotic HAL is dopamine-2 (D2) and sigma-1 (ai) receptor 
antagonist with apoptotic activity118'119'120. HAL is involved in neurotoxicity, causing clinically 
troublesome adverse events such as extrapyramidal and cardiac side-effects121. The "gold-
standard" neuroleptic HAL has been reported to be a calcium and calmodulin antagonist122, and 
was also demonstrated to efficiently inhibit PAP-formation from APP123. The mechanism by 
which it might exert such an effect is not known. However, HAL and other traditional 
antipsychotics have several adverse effects. Therefore, the use of atypical antipsychotics is 
taking over medical indications of conventional neuroleptics with very much success without 
notable side effects124'125'. The widely used high-potential atypical antipsychotic risperidone 
(RISP) is a potent D2-, 5HT2- and NA-antagonist with less adverse effects. RISP has no known 
effect on AD pathology, including APP metabolism. 
In light of evidence that HAL, one of the most frequently prescribed antipsychotic medications 
used in the treatment of SCH126, interferes with Ca -homeostasis122 and APP processing123, we 
evaluated it for its effects on pAP-induced Ca2+-imbalance in vitro and its role on APP 
metabolism. To gain more insight on its cellular effects at the molecular level, we have also 
studied its role on gene expression in vivo. In the course of surveying a wide variety of agents 
directed against PAP-toxicity, we also examined RISP with respect to [Ca2+]i, APP and gene 
expression profile. 
9 
EXPERIMENTAL PROCEDURES 
Participants 
- Demographics 
Primary cultures of human fibroblasts and suspension of lymphocytes were obtained and 
prepared from forearm skin-biopsies and blood samples after informed consent from 
participants. Sporadic AD patients of late-onset and age-matched controls volunteered as 
donors (Table I). 
Table I: Demographic data of participants 
Sporadic late-onset AD patients and age-matched controls volunteered as donors. 
Selection of individuals was made after their informed consent. Fibroblasts were 
harvested from forearm excisional biopsies; lymphocytes were separated from 
venous blood samples drawn in the usual fashion. 
Studies on fibroblasts Studies on lymphocytes 
Age of donors Number of Age of donors Number of 
(meart±SD) volunteers (mean±SD) volunteers 
Control 71±8.8 8 66.8±10.2 12 
AD 73±10.11 8 71 ±8.5 10 
At the time of obtaining samples, every single individual was outpatient. The diagnosis of AD 
was made according to DSM-IV criteria3. All AD donors met the DSM-IV definition of 
dementia of the Alzheimer's type, which requires evidence of cognitive deficits (criterion A) 
and a process of decline from previous levels (criterion C); none of them had history of familial 
AD. Control individuals were tested negative for any forms of dementia. 
- Medications 
None of the participants in our study received any medication known to interfere with calcium 
metabolism, such as antihypertensive drugs, calcium-antagonists, or antidepressants. None of 
the patients was on AchEIs before and during the measurements. 
Culture methods 
- Fibroblast culturing 
For outgrowth of fibroblasts, small pieces of skin material were placed in cell culture flasks 
(25cm2) and grown for 3-5 weeks in Dulbecco's modified Eagle's medium (DMEM) 
containing 5% of heat inactivated fetal calf serum (FCS) as well as penicillin (100 U/mL), 
streptomycin (100 pg/mL) and 2mM glutamate in a humidified atmosphere of 95% air and 5% 
of C02 . Cells were detached for serial passaging using 0.01% of trypsin and 0.02% of EDTA. 
Stocks of each cell line (passage number: 5) were frozen to -80°C and stored at -130°C until 
use. After thawing and/or trypsinization, cells were used to seed on glass coverslips, lOmms in 
diameter, pretreated with collagene, in a 24-multiwell plate in the DMEM medium containing 
5% of FCS. Cultures maintained in this way were generally confluent by day 7 and were used 
directly for measurements of [Ca2+]j. 
To monitor the long-term effect of PAP, a single sample was used for chronic culturing. Here, 
the seeding-and-passaging cycle was repeated as needed. In short, after 7 days in vitro, cells 
developed a monolayer, and subcultures were provided by trypsinization. 
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All fibroblasts had a characteristic spindle-shaped appearance and were attached firmly to the 
coverslips. 
- Separation of lymphocytes 
Blood samples were gently layered on Ficoll solution, and were centrifuged at 1800 rpm for 20 
mins. Lymphocyte-containing bands were rinsed with phosphate-buffered saline (PBS) three 
times. Cell concentration was estimated using Burker's chamber. Lymphocytes in PBS were 
used for measurements of [Ca2+]i. 
- Viability 
Viability of cells was estimated by the method of intravital staining with Trypan Blue after 
exposition of cells to the preparation (0.2% Trypan Blue in Hank's balanced saline solution, 
HBSS). After 5 minutes of incubation in the solution, less than 2-3% of fibroblasts and 
lymphocytes absorbed the dye. In line with this finding we concluded that more than 97-98% of 
cells present in the cuvettes were viable. 
- Treatment 
Cells were cultured in the presence of 10"7M, lOng/mL127,128 and/or 50pg/L129,130 final 
concentrations of pAP, HAL and RISP, respectively. HAL and RISP - designated for 
intravenous use - were purchased commercially (Haloperidol®; Gedeon Richter Ltd and 
Risperdal®; Ris-Int-63, Ref.No.: 336341; Janssen-Cilag, division of Johnson&Johnson Ltd., 
Hungary, respectively) and were used directly on the cells without further purification or 
sterilisation. Final concentrations of these antipsychotics were calculated in accordance with 
their therapeutic blood levels. 
Fibroblasts and lymphocytes used for control study were free of any treatment. 
Measurements of [Ca2+]j 
- Fluorescence imaging 
[Ca2+]i's were quantified by fluorescence ratio imaging of the calcium indicator dye Fura-2AM. 
Cells were incubated for 20-30mins at 37°C in the presence of lpM of the acetoxy-methylester 
form of Fura-2AM. Cultures loaded with the dye were then washed twice with PBS solution 
and were transferred to cuvettes containing PBS at 25°C for measurements. Fluorescence 
imaging in standard lxlcm cross section quartz cuvettes were performed with Hitachi F-2000 
spectrofluorimeter. The ratio of the fluorescence emission of the cultures using two different 
excitation wavelengths of 340nm and 380nm, at emission wavelength of 495nm was applied to 
determine [Ca2+]j. Values of the 340/380 fluorescence excitation ratio at 495nm emission 
wavelength (FL340/380), which represents the [Ca2+]i, were computed after each fluorescence 
measurement. In line with several papers examining calcium levels43'114,131, the authors found 
the rate of the fluorescence ratios to be more informative of the change of the calcium-level 
than the absolute values of [Ca2+]j. 
- Validity of Fura-2AM labeling 
To check that loading of the cells with the dye and intracellular cleavage of the ester occurred, 
we sampled the fluorescence excitation ratios before and after loading the cultures with the dye. 
In case of fibroblasts, ratios of unloaded cells observed at 495nm were 10.67±3.26, around 3-
times lower when compared to the ratio of 35.43±8.03 after incubation with the dye. As for 
lymphocytes, sampling of the fluorescence excitation ratios after incubation with the dye 
revealed 79.89±10.11, which represents a roughly 10-fold increase from the unlabeled ratio of 
7.68±2.2. This is characteristic of Fura-2AM fluorescence. 
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No significant alteration was detectable among labeled cultures in Fura-2AM fluorescence 
using the calcium-insensitive excitation wavelength of 367nm, indicating that the observed 
response reflects a real change in the calcium-level of the cells. 
- Protein content of cultures 
Because gross alterations in the cell number/cell mass actually present in the cuvettes may 
interfere with the fluorescence intensities, the total protein content of the samples was 
determined according to Lowry et al132. Coverslips with control fibroblasts were found to 
contain 146.9*8.4jxg protein/coverslip, whereas Alzheimer cells contained 139.1±5.1p.g 
protein/coverslip. Protein content of control lymphocytes revealed 252.1*11.6pg 
protein/cuvette, and cultures of AD leucocytes contained 239.9±14.0pg protein/cuvette. This 
difference is not significant in statistical terms, suggesting that the total protein content of 
Alzheimer and control cells did not differ considerably. 
- Rationale of the effect ofpAP, HAL and RISP 
During the experiments, the treated and control cell populations were cultured in media of 
identical composition except for the presence or absence of PAP, HAL and/or RISP. Therefore, 
it is reasonable to conclude that the observed difference in the 340/380 fluorescence excitation 
ratio of Fura-2AM-loaded cells is only associated with the presence or absence of the agents 
used, and hence can be regarded as an effect induced by PAP, HAL and/or RISP itself. 
Synthesis and purification of PAP 
- Amino acids 
All amino acid derivatives, solvents, chemicals and the resins were obtained commercially and 
were used without further purification. Protected amino acids used in the syntheses were of the 
L-configuration. The a-amino function group was protected with tert-butoxy-carbonyl (Boc) 
group, and the reactive side chain functional groups were protected as follows: para-toluene-
sulfonyl for Arg, cyclohexyl for Asp and Glu, benzyl-oxy-carbonyl for His, 2-chlorobenzyl-
oxycarbonyl for Lys, benzyl for Ser, and 2-bromobenzyl-oxycarbonyl for Tyr. The side chains 
of Asn and Gin were unprotected. 
- Solid phase peptide synthesis 
pAP was prepared by solid phase methodology133 using ABI-430A automated peptide 
synthesizer. For peptides with an amidated carboxy-terminus, para-methyl-benzhydryl-amine 
(MBHA) resin (0.57mmole/g) and for peptides with free carboxy-terminus Merrified resin 
(lmmole/g) was used. The coupling reactions were achieved with 3-fold excess of Boc-amino 
acids using DCC or DCC/HOBt as activating agent in dichloro-methane, dimethyl-formamide 
or a combination of thereof. Boc-Asn and Boc-Gln were coupled with preformeid 1-hydroxy-
benzotriazole ester to avoid side reactions. After a coupling time of 2 hours, the completeness 
of acylation was monitored at each stage by the standard ninhydrin test134. In cases where 
incomplete coupling was found, the coupling procedure was repeated, or the acetylation was 
carried out before the removal of the N-a-amino protecting group prior to the coupling of the 
next amino acid. Acetylation was performed with 30% of acetic anhydride in dichloro-methane 
for 10 and 20 minutes. Intermediate deblocking was achieved with 50% of trifluoro-acetic acid 
in dichloro-methane containing 0.5% of dithio-threitol followed by neutralization with 10% of 
triethyl-amine in dichloro-methane. Final deprotection as well as the cleavage of the peptides 
from the resin were performed with anhydrous hydrogen fluoride in the presence of 8% of 
anisol, 2% of dimethyl-sulfide, 2% of p-cresol, and 2% of thio-cresol at 0°C for 60 mins. After 
the removal of the hydrogen fluoride under a steam of nitrogen and in vacuo, the free peptides 
were precipitated with diethyl ether, filtered, washed with diethyl ether and extracted with 95% 
of TFA, diluted with water, and lyophilized. 
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- Purification 
Crude peptides were purified by using a Shimadzu LC-8A preparative HPLC system equipped 
with Backbond WP-C4 column (300x47 mm, 300A pore size, 15-20 pm particle size). The 
column was eluted with a solvent system consisting of (1) 0.1% of aqueous trifluoro-acetic acid 
and (2) 0.1% of trifluoro-acetic acid in 80% of aqueous aceto-nitrile in a linear gradient mode 
for 30 minutes at 80mL/min flow. The eluent was monitored at 220nm. The fractions were 
checked by analytical HPLC, and those with purity higher than 95% were pooled and 
lyophilized. The HPLC analyses of the peptides were carried out with a Hewlett-Packard 
Model 1050 liquid chromatograph using a Nucleasil 300 C4 (280x4 mm) reversed-phase 
column and a gradient elution with two solvent systems described above at a flow rate of 
lmL/min. The peaks were monitored at 220nm. Amino acid analyses of the purified peptides 
were carried out on a Hewlett-Packard Amino-Quant amino acid analyzer after hydrolysis of 
the samples in 6 M of hydrochloric acid at 110°C for 48hrs in tubes sealed under vacuum. 
Amino acid analysis of the hydrolysates of peptides showed the expected amino acid 
composition (data not shown). Data of electrospray mass spectrometry (ES-MS, FinniganMat 
TSQ 7000 mass spectrometer) were in accordance with the calculated average molecular 
masses. 
- "Aging" of the peptides 
Freshly prepared aqueous PAP solutions were "aged" for 1 hour before use. 
Treatment of animals 
Male, Sprague-Dawley rats weighing 200-250g were maintained in plastic cages (three per cage) 
containing wood shavings and were given rodent chow and filter-purified tap water ad libitum. 
Murines were housed in rooms of our animal facility maintaining temperature of 25±2°C and a 12-h 
light/dark cycle. 
All rodents were in good condition, and showed no signs of stress. Each was allowed to acclimate 
to the housing conditions for 1 week prior to beginning the experiment. With respect to the 
traditional antipsychotic haloperidol (Haloperidol®; Gedeon Richter Ltd, Hungary), groups of six 
rats were injected intra-peritoneally (i.p.) on a daily basis with therapeutic (0.05mg/kg) or toxic (0.5 
mg/kg) doses dissolved in saline ' . In case of the atypical drug risperidone (Risperdal®; Ris-Int-
63, Ref.No.: 336341; Janssen-Cilag, division of Johnson&Johnson Ltd., Hungary), therapeutic 
(O.lmg/kg) or toxic (1.0 mg/kg) doses, dissolved in water, were administered ' . Control rats 
received the vehicle alone. No other animals were housed in the room or allowed contact with the 
study animals. 
Experiments were performed in accordance with a protocol approved by the university ethics 
committee on laboratory animals. 
Preparation of rat cortical samples 
After acute (6, 12, 24 and 96 hours) and chronic (1, 2, 3 and 4 weeks) administration of the 
antipsychotics in both therapeutic and toxic doses, rats were decapitated under ether anesthesia. The 
cerebellum was removed and the fronto-temporo-parietal cortices were dissected. In order to 
eliminate post-mortem decay, preparation was performed on dry ice. The samples were 
homogenized in 50mM of Tris buffer (pH 7.5) containing 0.15M NaCl, 2mM phenyl-methyl-
sulfonyl-fluoride, 2mM EDTA, 2 pg/mL leupeptin, 1 pg/mL pepstatin, 1% Nonidet-P-40 and 0,1% 
sodium deoxycholate by using a glass-teflon potter (1500 rpm, 1 min). The homogenates were 
centrifuged at 10,000 x g for 30mins at 4°C. The supernatants were used for the detection of total 
APP. Protein concentrations of samples were determined by the method of Folin as modified by 
Hessetal.139 
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Western immunoblot 
Proteins (30pg/lane) were separated on a 9% of sodium-dodecyl-sulfate (SDS)-polyacrylamide gel 
and electroblotted onto nitrocellulose membranes by using the BioRad Mini-Protean II system. 
After protein quenching with 5% non-fat dry milk in 50mM of Tris-buffered saline (TBS, pH 7.5) 
containing 0.2% of Tween-20, the blotted samples were incubated overnight at room temperature in 
monoclonal 22C11 antibody (5 pg/mL, against residues 68-81 of APP). After being washed (5x), 
the membranes were incubated with horse-radish-peroxidase (HRP)-conjugated anti-mouse-IgG 
(1:500, Sigma-Aldrich, USA). For the detection of blots, the Renaissance Western Blot 
Chemiluminescence Reagent (Pierce, USA) was employed, followed by exposure to an 
autoradiographic film. Optical densities of immunoreactive bands were detected and quantified by 
means of the NIH-Image Analyser Program (NIH, USA). The levels of APPs in the control group 
were taken as 100%, and changes were calculated with respect to this value (data are given in 
relative units). 
Microarray Protocols 
- Samples and RNA preparation 
Total RNAs were extracted and purified from rat fronto-temporo-parietal cortices 
(40mg/animal) using NucleoSpin RNA purification kit (Macherey-Nagel, Diirren, Germany) 
according to the manufacturer's instructions. The quantity and the quality of all RNA 
preparations were assessed by gel electrophoresis and spectrophotometry (optical density: 
OD260/OD280 ratios) (NanoDrop, Rockland, DE, USA). RNA samples were aliquoted and 
stored at -80°C. Total RNA was used for microarray analysis as well as for Real-time 
quantitative reverse transcription-PCR (QRT-PCR). 
- Construction of microarrays 
8,000 cDNA inserts (amino-modified oligo-nucleotides) from rat mixed-tissue cDNA libraries 
(peripherial ganglion, brain, heart, etc.), containing named genes, expressed sequence tags 
(ESTs), housekeeping genes and genomic control spots (Sigma-Operon) were resuspended in 
50% dimethyl-sulfoxide/water at a final concentration of 300finol/pL. Oligonucleotides were 
arrayed from 384-well plates onto PXM oligo-nucleotide slides (Full Moon Biosystems, 
Sunnyvale, CA, USA) by using a MicroGrid Total Array System (BioRobotics, Cambridge, 
UK) spotter with 16 pins in a 4x4 format. DNA elements were deposited in duplicate in distinct 
area of the array. The diameter of each spot was approximately 200 pm. After printing, slides 
were incubated in a humid chamber for 14h at 42°C. Prior to hybridization, the slides were 
processed as described previously140'141. 
- Microarray probe preparation and hybridization 
For probe preparation, 2pg of total RNA was reverse transcribed using poly-dT primed 
Genisphere Expression Array 900 Detection system (Genisphere, Hatfield, PA, USA) in 20pL 
total volume using 20 units of RNAsin (Fermentas, Vilnius, Lithuania), lx first strand buffer 
and 200 units of RNAse H(-) point mutant murine myeloid leukemia virus (M-MLV) reverse 
transcriptase (Fermentas, Vilnius, Lithuania). All other probe preparation steps were done 
according the manufacturer's instructions (Genisphere, Hatfield, PA, USA). Both the first step 
cDNA hybridization and the second step capture reagent hybridization were carried out in a 
Ventana hybridization station (Ventana Discovery, Tucson, AZ, USA) by using the "antibody" 
protocol. First hybridization was performed at 40°C for 6h in "FGL2" hybridization buffer (10x 
Denhart solution, 0.25M sodium phosphate buffer pH: 7.0, ImM EDTA, lx SSC, 0.5% SDS), 
then 2.5pL of each Cy5 and Cy3 capture reagents were added to the slides in 200pL "Chiphyb" 
hybridization buffer (Ventana Discovery, Tucson, AZ, USA) and incubated at 42°C for 2h. 
After hybridization, the slides were washed in 0.2xSSC twice at RT for lOmin, then dried and 
scanned. 
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- Scanning 
Each array was scanned under a green laser (543nm for Cy3 labeling) or a red laser (633nm for 
Cy5 labeling) using a ScanArray Lite (GSI Lumonics, Billerica, MA) scanning confocal 
fluorescent scanner with 10pm resolution (Laser power: 85% for Cy5 and 90% for Cy3, Gain: 
80% for Cy5 and 75% for Cy3)142. Scanned output files were analyzed using GenePix Pro5.0 
software (Axon Instruments Inc., Foster City, CA, USA). Each spot was defined by automatic 
positioning of a grid of circles over the image. For each channel the median values of feature 
and local background pixel intensities were determined142,143. The background-corrected 
expression data were filtered for flagged spots and weak signal. Technical replicates on the 
same array were averaged. Data were excluded in cases where technical replicates were 
significantly different. Normalization was performed using the print-tip Lowess method144,145, 
followed by Student's t-test in order to determine the genes to be regarded as regulated in 
response treatment. Logarithm was taken from each expression ratio to fulfill the /-test's 
requirement for a normal distribution. Genes for which the mean of log-ratios across the 
biological replicates was equal to zero at a significance level a=0.05 are considered to have an 
unchanged expression. On the other hand, genes having a P value smaller than a and the 
average-fold change (increase or decrease) of the four data points were at least 2.0-fold were 
considered as regulated genes. 
- Expression profile verification 
QRT-PCR was performed on a RotorGene 2000 instrument (Corbett Research, Sydney, 
Australia) with gene-specific primers and SybrGreen protocol to confirm the gene expression 
changes observed by microarrays. 2pg of total RNA from each sample was reverse transcribed 
in the presence of poly(dT) sequences in a total volume of 20pL. After dilution with20 pL of 
water, lpL of the diluted reaction mix was used as template in QRT-PCR. The 20pL reaction 
volume contained 0.2mM of dNTP, 1* PCR reaction buffer (ABGene, Epsom, UK), 6mM of 
each primer, 4mM of MgCb, 1* SYBR Green I (Molecular Probes, Eugene, Oregon, USA) at 
final concentration, and 0.5 units of thermostart Taq DNA polymerase (ABGene, Epsom, UK). 
The amplification was carried out with the following cycling parameters: 600 sec heat start at 
95°C, 45 cycles of denaturation at 95°C for 25sec, annealing at 60°C for 25sec and fluorescence 
detection at 72°C for 15sec. Relative expression ratios were normalized to P-actin. Non-
template control sample was used for each PCR run to check the genomic DNA contaminations 
of cDNA template. Analysis of results was performed by Pfaffl method146. Using this 
calculation method differences between the amplification efficiencies of reactions could be 
corrected. 
Data analysis 
Results presented are "arithmetic means ± standard deviation" of experiments performed in 
triplicate. Data were analyzed using Excel 98 (Microsoft, Redmond, WA) utilizing Student's /-test 
to determine the significance of observed changes. All differences stated in the text are statistically 
significant (P<0.05). 
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RESULTS AND DISCUSSION 
1. involvement of the periphery in AD 
1. a. [Ca2'], of lymphocytes 
Lymphocytes were successfully harvested and purified on Ficoll gradient from both 
Alzheimer and control donors. Cells were 97-98% viable as confirmed by intravital 
staining with Trypan Blue, and were competent to be labeled with Fura-2AM at 37°C by 
passive diffusion during the experiments. The ratio of fluorescence at 340 and 380nm 
(FL340/380) representing [Ca2+]i of control cells was 1.001 ±0.117, whereas Alzheimer 
lymphocytes exhibited a ratio of 1.131±0.100 (Table II). These findings indicate that AD 
cells demonstrate increases in free cell calcium when compared to leukocytes of age-
matched controls. 
Table II: FL340/38o of lymphocytes 
Comparative fluorimetric measurements on lymphocytes of human Alzheimer and 
control donors on FL340/38o using Fura-2AM. Resting [Ca2'], appeared to be higher in 
AD cells when compared to that seen with control lymphocytes. After incubating 
cells in the presence of PAP, the [Ca2"]j of the control cells elevated, while that of 
AD lymphocytes did not differ considerably. (T<0.05) 
Samples FL340/380 Number of 
(mean±SD) cuvettes 
Control 1.001±0.117 23 
Alzheimer 1.131±0.100* 18 
Control+ßAP 1.507±0.368* 23 
Alzheimer+ßAP 1.130±0.075 18 
Lymphocytes of our sporadic AD patients were distinguished from normal ones in our 
experiments, which clearly shows that detectable biochemical alterations are present in 
Alzheimer lymphocytes. Considering PAP central to AD pathomechanism, elevated [Ca2+], 
of AD cells is broadly in line with the notion that PAP has the potential to increase Ca2+-
levels43'44'49'65'66. However, serum PAP-level in AD patients does not significantly differ 
from that seen in healthy individuals to convincingly explain the findings. Moreover, PAP 
is considered a physiological peptide19"21; it exerts pathologic effects either in its 
aggregated form27, or its cytotoxicity has been attributed to attending intracellularily35"37. 
Nevertheless, even though blood concentrations of PAP is not significantly higher, its level 
might be slightly elevated enough to disrupt Ca2+-homeostasis in lymphocytes, and AD-
specific changes in PAP aggregation or distribution inside the cells might be present to 
further the calcium-imbalance. 
To justify the Ca2+-rising effect of PAP, measurements of [Ca2+]j with the calcium 
indicator dye Fura-2AM in control lymphocytes maintained in the presence of 10"7M pAP 
for 2 hours revealed an increase in the 340/380 fluorescence excitation ratio (FLLYMPH: 
1.507±0.368), the mark of an increase in free calcium level during the 2-hour exposure 
period. By directly monitoring [Ca2+]j, we found that Alzheimer cells, maintained in the 
same conditions, showed no significant change in the free cell calcium (FLLYMPH: 
1.130±0.075). AD lymphocytes appeared to be resistant to PAP. 
These findings might be explained by our hypothesis which assumes that slightly, but 
chronically elevated serum PAP levels disrupt Ca2+ in a tonic manner, causing continuous 
Ca2 -overload into the neurons. This may indirectly confirm why resting [Ca2+]j of 
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untreated AD lymphocytes is higher than that of control ones. The incessant amyloid-
stimulus will ultimately make lymphocytes resistant to PAP. Furthermore, PAP can cause 
sustained alterations in cell membrane fluidity163. Aggregated and intracellular PAPs 
interact with membrane structures (both protein-peptide and lipid-peptide interactions), 
which can cause permanent change in the structure of the cell membrane and in [Ca2+]j. 
These alterations might promote the resistance of lymphocytes to PAP with respect to 
[Ca2+]i. 
Because Ca2+ is a central secondary messenger, tonic elevation of its concentration has 
various effects. In blood, Ca2+ plays role in activation of lymphocytes. 
Elevation of intracellular free Ca2+ is one of the key triggering signals for T-cell activation 
by antigen. PAP is known to interfere with various (including Ca +- and K+-) channels, and 
is able to form non-selective cation pores in the cell surface, both known to yield elevated 
intracellular free Ca2+-levels. Tonic pAP-trigger may lead to incessant antigen-independent 
activation and clonal expansion of lymphocytes, which is required to generate an efficient 
generalized immune response to a specific antigen (eg. PAP). However, the immune 
system is complex enough that activation of CD4 T-cells can lead to several different 
functional outcomes: activation and cytokine secretion, death, or functional non-
responsiveness (anergy). 
Activation of lymphocytes in AD by Ca2+ might be of critical importance. When 
Alzheimer first described the clinical and pathologic features of the dementing disorder in 
early 1900s, he noticed signs of an inflammatory reaction; however, only in the last decade 
has the notion that the brain is "immunologically privileged" begun to be dismissed as an 
oversimplification, supported by mounting evidence that senile plaques and NFTs in brains 
of patients with AD are associated with a unique endogenous inflammatory reaction that is 
orchestrated by microglial cells. Activated microglia, the residing macrophage of the brain, 
in conjunction with astrocytes, which sustain the functional integrity of neurons, contribute 
extracellular matrix proteins, and can be considered to be cells of the innate immune 
system, are central to the inflammatory hypotheses for the neurodegenerative processes 
that are associated with AD. Microglial activation may be induced by soluble PAP 
fragments through causing Ca2+-imbalance, plaque deposition, degenerating neurons, or all 
three. Activated microglia may release neurotoxins, toxic inflammatory mediators, and free 
radicals, but may also be involved in scavenging PAP. Inflammatory stress may increase 
generation of PAP through upregulation of APP. Apart from directly activating microglia 
by increasing [Ca2+]j, PAP might also circuitously stimulate microglia. This activatory 
scenario might not uniquely happen in the CNS. 
It is well established that cross-talk takes place between the brain and the peripheral 
immune system. CD4+ helper cells are triggered by peptide antigens bound to class IIMHC 
molecules. A class II allele that can bind to a given self-antigen (eg. amyloid-aggregate) 
may facilitate an autoimmune response. T-cell antigen receptor (TCR) is comprised of a 
ligand-binding subunit, the a and P chains, and a signaling subunit, namely the CD3 units. 
The physiologic ligand for the TCR is foreign peptide bound to the MHC expressed on 
APCs, including dendritic cells, macrophages, and B cells. PAP may bind to either units, 
and therefore fibrillar pAP deposits and PAP fibrils may serve as activator of the immune 
system both in and outside of the CNS. Activation of autoreactive (amyloid-reactive) T-
cells in periphery leads to release of cytokines/adhesion molecules and passage of cells 
through altered blood-brain-barrier into CNS. 
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Activated lymphocytes do penetrate into the normal brain in small numbers147 and, during 
CNS inflammatory reactions, such as in AD, their migration is dramatically upregulated14 . 
Leptomeningeal infiltrates primarily around amyloid-laden blood vessels with T-
lymphocytes (mostly CD/ type) suggests that lymphocytes freely enter the brain in AD149. 
In order for leukocytes to perform their immune function in tissue surveillance they must 
be capable of leaving the vasculature and entering tissues. The way in which specific 
leukocyte subsets may achieve this in different vascular beds is in many cases unresolved. 
In the CNS, extravasating leukocytes must penetrate the highly impermeable tight 
junctions, which link the vascular endothelial cells, or use an alternative unresolved 
parajunctional mechanism. However it is apparent that whichever mechanism is used for 
leukocyte diapedesis, the cells of the blood-brain barrier are not passive in this respect and 
are actively involved in facilitating lymphocyte migration into the CNS. Ca2+-mediated 
intracellular events are essential for lymphocyte migration through the blood-brain 
barrier150, as triggered by pAP. 
T-cells cross the intact blood-brain-barrier, home to neuritic plaques, and cause local 
inflammation either directly, or by activating microglia. However, relatively few T- and B-
lymphocytes are detected in the vicinity of plaques. Nonetheless, an increase in the levels 
of IFNy, the principal Tm cytokine, is correlated with the severity of AD 151 by 
synergistically enhancing the PAP-dependent microglial activation, resulting in neuronal 
cell injury152. This hypothesis is confirmed by the finding that the activity of certain Th2 
cytokines, such as IL-10, which seem to be potent in reducing the activity and 
neurotoxicity of microglia, is reduced in patients with AD, and a decrease in the numbers 
and activity of suppressor T-cells has been reported151. Therefore, local inflammatory up-
regulation seen in the brains of patients with AD may arise from an inadequately regulated 
systemic immune response153, presumably triggered by pAP. 
A complete understanding of these signaling mechanisms may lead to the identification of 
target pathways for the therapeutic treatment of brain inflammatory disorders, including 
AD. In addition, by understanding the mechanisms responsible for triggering lymphocyte 
migration it may be possible to manipulate peripheral blood lymphocytes to deliver 
therapeutic agents, that are normally excluded by the blood-brain barrier, to the CNS 
particularly in inflammatory diseases where these cells would be self targeting. During an 
influx of leukocytes, the initial interaction of the infiltrating cells is with the endothelial 
lining of the vessels. After migration through the endothelium, however, the principal 
interaction of leukocytes is with fibroblasts. This interaction is mediated through the 
increased expression of intercellular adhesion molecule-1 (ICAM-1). An immediate 
response to the cross-linking of ICAM-1 on fibroblasts or endothelial cells is the triggering 
of a rise in [Ca2+](154, and activation of NF-KB, which is a transcription factor ubiquitously 
associated with the induction of a range of pro-inflammatory cytokines and adhesion 
molecules155. Therefore, the Ca2+ homeostasis of Alzheimer fibroblasts has also been 
examined in this study. 
l.b. [Co2*] i of fibroblasts 
Seven days after seeding, cultured fibroblasts from both Alzheimer and control donors 
were 80% confluent. More than 97-98% of cells on coverslips were viable as confirmed by 
intravital staining using Trypan Blue. Cells were competent to be labeled with Fura-2AM 
at 37°C by passive diffusion during the study. With respect to control cultures, FL340/380 
revealed 2.48±0.162, whereas Alzheimer fibroblasts exhibited a ratio of 2.052±0.207 
(Table III). Just as with lymphocytes, fibroblasts of our sporadic AD patients were also 
distinguished from normal ones in our experiments, demonstrating detectable biochemical 
alterations in Alzheimer fibroblasts. 
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Table III: FL^ooso of fibroblasts - short-term study 
Comparative fluorimetric studies on human control and Alzheimer fibroblasts on 
F L 3 4 0 / 3 8 O using the Ca2l"-indicator dye Fura-2AM. Cells were maintained with or 
without (iAP for 16 hours at 37°C. The fluorescence excitation ratios were calculated 
from fluorescence intensities observed at 495nm using dual wavelength 
spectrofluorimetry (excitation wavelengths: 340 and 380nms). Alzheimer cells 
exhibited lower [Ca2+]i when compared to the control cultures. Exposure of 
fibroblasts to pAP resulted in increased [Ca2+]j of the control cells, but not of AD 
cultures. (*P<0.05) 
Cultures FL340/380 Number of 
(meaniSD) coverslips 
Control 2.48±0.162 16 
Alzheimer 2.052±0.207* 42 
Control+ßAP 2.666±0.08* 16 
Alzheimer+ßAP 2.055±0.125 42 
These findings indicate that cultured cells from donors of AD demonstrate significant 
decreases in resting free cell calcium when compared to that of age-matched controls. 
However, when taken together with leukocytes, the resting free calcium of AD 
lymphocytes is apparently opposing that of AD fibroblasts, in that basal [Ca2+]j of 
fibroblasts from AD patients is significantly lower, whereas [Ca2+]j of lymphocytes is 
higher than that of the matched controls. To reconcile these opposite changes in AD cells, 
PAP-induced biochemical alterations were also studied in fibroblasts. 
Exposure of cells to PAP for 16 hours caused a rise in free cell calcium only in control 
cultures (FL340/380: 2.666±0.08). PAP apparently disrupts calcium-regulating processes in 
control cells resulting in elevations of free cell calcium. This finding is in line with 
previous reports43'109'114'131, demonstrating elevated calcium level as an underlying 
pathomechanism of PAP-induced cellular degeneration. However, AD cells do not show 
this response. Alzheimer cultures maintained in the same conditions showed little or no 
change in [Ca2+]j, with the fluorescence ratio being 2.055±0.125 (Table III). Alzheimer 
fibroblasts, like lymphocytes, are therefore refractive to PAP. These results are in line with 
findings demonstrating a decreased PAP-sensitivity in Alzheimer cells156'157. 
Rise in [Ca2+], results in triggering of various pathways of a particular cell. As discussed 
with the immune system, B-cell receptor (BCR)- and TCR-signaling is initiated through 
the actions of non-receptor tyrosine kinases in conjunction with B- and T-cell-specific 
adaptor proteins, transduce signals required for the activation of the downstream signaling 
pathways, including Ca2+158. Just as with lymphocytes, fibroblasts are also activated by 
Ca2+-signals. In this scenario, fibroblasts undergo activation and secrete cytokines. 
Upregulation of mRNA encoding for the inflammatory cytokines IL-lp and IL-6 as well as 
for chemokines IL-8 and MCP-1 might therefore represent potent activators of local 
inflammatory cytokine and chemokine production159 to activate lymphocytes. Signaling 
through ICAM-1 provides a co-stimulatory signal with that of CD3 leading to T-cell 
proliferation, migration, and the induction of cytokines 160. Migration is primarily 
dependent on the stage and mode of lymphocyte activation, and activated T-cells, 
irrespective of their antigen specificity, are able to penetrate the blood-brain barrier161. 
ICAM-1, overexpressed by activated fibroblasts and lymphocytes, is central to the 
migration of T-cells into the CNS162. Production of cytokines, moreover, may indirectly 
lead to microglial activation in the brain. 
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The most parsimonious explanation for the role of fibroblasts in AD is, therefore, 
activating members of the immune system, including T-cells and microglia. Both processes 
may be initiated by PAP. In order to suppress the PAP-induced activation of both 
fibroblasts and lymphocytes in AD, several pharmacological interventions should be 
considered. The use of Ca2+ channel blockers (L-type calcium blockers, such as verapamil, 
diltiazem and nifedipine; non-selective calcium blocker amlodipine, etc.), activating 
plasma membrane Ca2+-ATPase, overexpression of SR/ER Ca2+-ATPase, mitochondrial 
targeting, and NF-AT signaling pathway targeting may be promising. 
pAP-induced rise in the [Ca2+]i leads to activation of fibroblasts and therefore participates 
in lymphocyte migration. Interestingly, however, AD fibroblasts demonstrate decreases jp 
the resting free Cer+ when compared to control cells. 
1. c. Long-term effect of P-amyloid 
Short-term (8-16 hours') exposure of cultures to pAP resulted in elevation of the 
fluorescence ratio (FL: 2.691±0.121), which is an indicative of the increase in the [Ca2+]i 
(Table IV). This finding is in line with previous reports, demonstrating that a sustained rise 
in the basal calcium level is one of the underlying pathomechanisms of neural 
degeneration. The PAP-induced increase in the [Ca2 +]j peaked in fibroblasts on the 4th day 
of exposure to the peptide (FL: 2.798±0.101), and turned into a plateau for around 16 
weeks (Figure 3). After the approximately 4 months' time the calcium-level of fibroblasts 
gradually started to decrease. Within 11 weeks, the [Ca2+]j became significantly lower in 
the cells (FL: 2.164±0.199) when compared to that of the resting levels seen with cultures 
before exposure to pAP (FL: 2.479±0.221). The decreased calcium-level appeared to be 
constant for 10 weeks. In contrast with fibroblasts exposed chronically to PAP, [Ca2+]i of 
control cultures did not change significantly over time (Table IV, Figure 3). 
Table IV: FL34o/38o of fibroblasts - long-term study 
Comparative fluorimetric studies on human fibroblasts on FL340/380 utilizing the 
Ca2+-indicator dye Fura-2AM. The cells were cultured with PAP for 37 weeks at 
37°C. The table marks a rapid increase in the FL340/380, representing elevation in 
[Ca2+]j. This elevation continues to be significant for 16 weeks, after which a decline 
in the calcium-level develops. The decrease in the fluorescence-ratio appears to be 
permanent. [Ca2+]j of untreated cultures did not change significantly during 37 
weeks. (*P<0.05) 
Duration of treatment PAP Control 
resting level 2.479±0.221 2.479±0.221 
8 hrs 2.691±0.121* 2.483±0.107 
16 hrs 2.666±0.080* 2.480±0.162 
-half-week 2.798±0.101* 2.475±0.200 
-16 weeks 2.802±0.157* 2.489±0.113 
-27 weeks 2.164±0.199* 2.469±0.132 
-37 weeks 2.165±0.176* 2.489±0.206 
Figure 3: Time-course of PAP on | C a 2 + | i of human fibroblasts 
Short-term exposition of fibroblasts to pAP results in an increased [ C a 2 + ] j . The rise in the calcium-level peaks after an approximately half-a-week treatment with the peptide. The 
flow-chart demonstrates that the reversible elevation of [Ca2+]< turns into a fall at around the 16th week of exposition to pAP, and yields a sustained decrease in the [Ca2t]j. Calcium-
level of control cultures with no PAP treatment appeared to be unchanged during the experiment. 
Fibroblast with ßAP - - Fibroblast without ßAP 
o 
••o 
2 « 
o e Qi V 
s u o 
s 
E 
2,5 
0 50 100 150 200 250 
Days 
21 
Treatment of control fibroblasts with PAP has resulted in a transient rise in the calcium-
concentration. Elevation in the [Ca2+]j appeared to be constant for 16 weeks, after which 
period the calcium level of cells gradually started to fall. Chronic exposition of fibroblast 
cultures to PAP, therefore, causes a decline in the calcium-level. This decrease was 
apparently sustained in our experiments. Thus, cells in our study have responded to PAP 
treatment in a time-dependent manner. Consistent with previous findings43'1'114'131, [Ca2+]i 
is increased as a result of PAP; this, however, seems to be only a short-term effect of the 
peptide. Piling evidence suggests that pAP interacts with cell membrane structures and also 
causes changes in membrane fluidity163. Exposure to PAP elicits sustained activation of 
Ca2+-permeable receptor channels, which results in a pathological enhancement of inward 
Ca2+-currents and a subsequent increase in the [Ca2"^50'131'1 . Elevation of [Ca2+]j may 
further progress through die activation of second messengers (eg. IP3) that mobilize 
intracellular calcium ions resulting in Ca2+-release from its intracellular stores165'166. We 
hypothesize that the acute rise in [Ca2+]i is attributable to these interactions of PAP. 
Chronic exposition of cells to pAP apparently decreases [Ca24]j. This observation is a real 
novum, and the exact pathomechanism behind this finding is yet unknown. Falling of the 
calcium-level may indicate that PAP causes a total ionic imbalance. Initially, pAP peptides 
can increase calcium influx through voltage-gated calcium channels (N- and L-type 
channels); form a cation-selective ion channel after PAP incorporation into the cellular 
membrane; reduce magnesium blockade of NMDA receptors to allow increased Ca2+ 
influx; and inhibit K+ channel and Na+/Ca2+ exchanger. Opening elevation of [Ca2+]i 
triggers Ca2+-mediated Ca2+-release from intracellular stores . Also, based on the channel 
hypothesis49, PAP may further the calcium imbalance by directly forming Ca2+-channels. 
As a result, [Ca2+]i may reach pathological levels which exhausts the buffering capacity of 
intracellular Ca2+-pools, particularly that of die mitochondria and endoplasmic reticulum. 
Due to the altered concentration gradient, Ca2+ is expelled from the cell through outward 
channels to compensate the Ca2+-overload. As a result of their pathological interaction with 
PAP, the function of Ca2+-exchangers and pumps that translocate Ca to the interstitium 
may become hyperactive and uncontrolled. These pumps transport Ca2+ from the 
cytoplasm to the extracellular fluid against large electrochemical potential gradients using 
energy from ATP, which causes an incessant outward calcium flow leading to a Ca2+ loss 
inside of the cell. This can not be balanced by the cells' internal buffer systems on the long 
term, yielding a sustained decrease in the [Ca2 +]i1 6 8 and loss of energy. At later stages, 
damage to the mitochondria results in the enhanced production of free radicals, and 
activation of factors involved in apoptotic cell death. Accordingly, chronic fall in Ca2+ 
predisposes cells to self-degeneration 69. As a result, derange of the intracellular calcium 
homeostasis ensues, and cells ultimately succumb to the chronic ionic imbalance. 
The biphasic Ca2+-response to PAP may play an important role in the pathomechanism of 
AD. Initially fibroblasts, activated by Ca2+, assist lymphocytic migration. A decreased 
calcium-level on the long-run, however, might deactivate fibroblasts. Dormant fibrocytes 
with no cytokine and ICAM-1 expression chronically arrest lymphocytic activation and 
migration to the brain through blood-brain-barrier. This may explain why relatively few T-
and B-lymphocytes are detected in the vicinity of neuritic plaques. 
Despite the major pathological findings in the central nervous system of Alzheimer 
patients, the present thesis, as well as previous studies, indicate that metabolic deficits 
occur in non-neuronal tissues, including fibroblasts and lymphocytes97"109. Interestingly, 
however, basal [Ca2+]j of fibroblasts is opposing that of lymphocytes. The difference 
between an increased [Ca2 +]j in lymphocytes and decreased [Ca *]i in fibroblasts may be 
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attributable to the specific ion-regulation of the respective cell-type, or to an altered 
affinity of PAP to different cells of peripheral tissues. To reconcile these opposite changes 
in AD cells, the fact that the turnover rate of cells in the blood is way higher than that of 
the fibroblasts may give a more convincing explanation. PAP initially increases the [Ca2+]i 
of cells, which has been demonstrated herewith and earlier43'109'114'1 , this correlates with 
an increase in the FL340/380 of the lymphocytes in this study. PAP, however, completely 
disrupts calcium homeostasis on the long run, resulting in a decreased resting calcium 
level, as seen with fibroblasts. On theoretical grounds as explained above, the [Ca2+]i 
would also be decreased in white blood cells, had they lived longer (ie. had their turnover 
rate been slower), like fibroblasts. 
Importantly, both AD fibroblasts and lymphocytes are resistant to PAP. Alzheimer cells -
in contrast to control ones - could be rendered resistant to PAP because of the chronic, 
long-term expositions, lasting several weeks (with respect to lymphocytes) or years (in 
case of fibroblasts), of cells to the peptide98. A tonic PAP-Ioad seen in AD ultimately 
decreases [Ca2+]j and makes cells insensitive to P-amyloid on the long run. 
PAP apparently has a time-dependent biphasic effect: acutely, it increases the calcium-
concentration of cells; in contrast, on the long-run, PAP acts as a calcium-antagonist. 
Therefore, the idea that PAP leads to neural degeneration solely by increasing cells' 
calcium concentration must be replaced with a more complex view of its dual function in 
intracellular ionic homeostasis. The neurotoxicity of PAP is therefore due to its dual effect, 
but mainly to its long-term calcium-antagonistic activity. The observed changes can be 
considered as long-term cell physiological action and can be used as a sensitive marker for 
testing for the long-term activities of PAP. 
These data signify that Alzheimer-specific biochemical alterations are present in the 
peripheral tissues. It is yet unknown whether these changes reflect the very dysfunctions in 
the brain, or these changes are specifically present only in the cell-types studied. Because 
fibroblasts express metabolic alterations that reflect dysfunction in other organs, such as 
the brain, it is reasonable to suggest that these changes might also be present in the CNS. 
These findings therefore may shed new light on understanding the pathomechanism of AD. 
This new observation on Ca + homeostasis might be used as a springboard for studying AD 
pathology, and for developing novel treatment options in AD. Moreover, fluorimetric 
differences in AD fibroblasts and lymphocytes might serve as useful models for 
establishing diagnostic tools in Alzheimer dementia, monitoring progression of the disease 
and responsiveness to treatments by screening biochemical alterations in the periphery. 
2. Role of antipsychotics in the periphery 
2. a. Effect of haloperidol on [Ccr /, offibroblasts 
[Ca2+]j of neither control, nor AD fibroblasts have changed significantly as a result of HAL 
treatment (FL340/380: 2.41*0.119, and 2.049*0.202, respectively). Preincubation of cultures 
with HAL together with PAP has also resulted in no elevation in [Ca24]j (Table V). 
In the brain, HAL has been previously reported to interfere with calcium metabolism 
through various mechanisms, including interaction with D2 and oi-receptors122,170'171. 
Moreover, HAL has been shown to induce apoptosis of brain cells, which involves 
activation of a-receptors, and also translocation of calcium into the cytoplasm171'172'173. 
Because differences certain to be encountered with respect to tissue-specific 
macromolecules, lack of various neuronal receptors on fibroblasts may give an 
explanation. Since fibroblasts do not express D2 and oi-receptors, HAL is not potent in 
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interfering with Ca2+ -homeostasis in cutaneous cells. However, other than receptor-
mediated pathways may also lead to HAL-induced changes in Ca2+-levels. Therefore, 
evaluating HAL for its effects on PAP-induced Ca2 "-imbalance on fibroblasts in this study 
was inevitable. 
Table V: FL340/38o of fibroblasts: treatment with haloperidol 
Comparative fluorimetric studies on human control and Alzheimer fibroblasts on 
FL 3 4 0 / 38O utilizing the Ca2'-indicator dye Fura-2AM. Cells were cultured with or 
without PAP and/or HAL for 16 hours at 37°C. Elevation in FL340/38O after PAP-
treatment was attenuated by co-administration of HAL. (*P<0.05, when samples 
compared to their untreated counterparts only) 
Cultures FL340/380 Number of 
(mean±SD) coverslips 
Control 2.48±0.162 16 
Alzheimer 2.052±0.207 42 
Control+PAP 2.666±0.08* 16 
Alzheimer+PAP 2.055±0.125 42 
Control+HAL 2.41±0.119 16 
Alzheimer+HAL 2.049±0.202 16 
Control+PAP+HAL 2.46±0.123 16 
Alzheimer+PAP+HAL 2.054±0.198 16 
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Co-administration of both PAP and HAL yielded unchanged Ca -levels of the cultures 
(Table V). This finding is important in light that pAP has proved to change [Ca2+]j, and 
might be explained on the basis that HAL has been shown to block Ca -channels ' . 
Evidence from a number of studies has demonstrated that PAP can form ion channels in 
lipid bilayers, liposomes, neurons and other cells49'175. pAP-channels are heterogeneous in 
size, selectivity, blockade, and gating. They exhibit multiple cation selectivity, admitting 
Ca2+, Na+, K+ , Li' 
, etc., leading to unregulated Ca2+-influx via PAP-channels. Based on the 
Ca2"-channel hypothesis of PAP, HAL may efficiently block the channel activity of PAP. 
Also, because HAL was demonstrated to efficiently inhibit pAP-formation123, the 
protective effect of HAL might be achieved through two connected mechanisms. HAL 
decreases the concentration of pAP; accordingly, less Ca2+-channels, formed of PAP, will 
be present. However, even these few channels are blocked by HAL. Moreover, HAL may 
act as a p-sheet breaker. This hypothesis strongly supports the theory that both regulating 
pAP production and blocking pAP-channels/pAP aggregation may underlie the molecular 
mechanism of HAL (neuro)protection. Therefore, HAL is a multimodal antagonist of PAP. 
Chronic treatment with HAL may result in decreased pAP-induced neurotoxicity in the 
brain over time through various, but not fully understood mechanisms as discussed above. 
This may explain why several investigators have found a low frequency of AD 
neuropathology in SCH, as many patients with SCH are likely to have been chronically 
treated with HAL, a commonly prescribed drug for this disorder. 
Because AD is frequently associated with BPSD, which is treated with antipsychotic 
• inc i nn 
medications such as haloperidol ' , future randomized controlled studies should target 
AD patients with BPSD with a history of chronic HAL treatment for neuropathologic 
examination. The prediction is that these patients should show a lower progression rate 
than untreated subjects or subjects treated with structurally divergent antipsychotic drugs. 
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Effect of risperidone on [Ca2fi, of fibroblasts 
Exposure to the atypical antipsychotic RISP alone did not significantly alter the [Ca2+]j of 
both control and AD fibroblasts, leaving the FL340/380 technically unchanged. This suggests 
that RISP itself does not interfere with Ca2+-homeostasis of these cutaneous cells. No 
significant alteration was observed when cells were co-treated with RISP and PAP (Table 
VI). 
Table VI: FL340/380 of fibroblasts: treatment with risperidone 
Comparative fluorimetric measurements on fibroblasts of Alzheimer and control 
donors on FL340/380 using Fura-2AM. Cells were maintained with or without PAP 
and/or RISP for 16 hours at 37°C. pAP-induced increase in FL340/380, representing a 
rise in [Ca2+]j, was efficiently antagonized by RISP. (*P<0.05, when samples 
compared to their untreated counterparts only) 
Cultures FL1340080 Number of 
(mean±SD) coverslips 
Control 2.48±0.162 16 
Alzheimer 2.052±0.207 42 
Control+PAP 2.666±0.08 16 
Alzheimer+pAP 2.055±0.125 42 
Control+RISP 2.479±0.200 16 
Alzheimer+RISP 2.054±0.172 16 
Control+pAP+RISP 2.482±0.114 16 
Alzheimer+pAP+RISP 2.053±0.099 16 
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Contrary to HAL, there is no information on the effect of RISP on Ca -homeostasis, nor 
on its ability to interfere with PAP production. However, activation of dopamine-receptors 
leads to transient increase in [Ca2+]j. Atypical antipsychotics, such as RISP, have been 
shown to stabilize [Ca2+]j through antagonizing dopamine-receptors. Furthermore, atypical 
but not classical neuroleptic drugs reduce astroglial dopamine-sensitivity178. Moreover, 
dopamine-receptor antagonists such as RISP, just as antioxidants, have been shown to 
protect neurons against the damaging effects of PAP and catecholamines179. 
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RISP did not change [Ca ]i, and alleviated PAP-induced Ca -imbalance. These very same 
phenomena were found in this study with respect to typical antipsychotic HAL, and 
therefore they may share common targets. When taken together with the hypothesis that 
fibroblasts may serve as models of several neurometabolic disorders including AD 1 14" 1 16, 
administration of RISP and HAL in the treatment of BPSD appears to be safe with respect 
to [Ca2+]j. Moreover, both RISP and HAL have proved to efficiently antagonize Ca2+-
disrupting cytotoxic effects of PAP. In spite of their inability to directly interfere with Ca2+ 
in the periphery, the observation that RISP and HAL efficiently attenuate PAP-induced 
Ca2 -imbalance further confirms the possibility that RISP and HAL directly interact with 
pAP. However, further studies are needed to evaluate the putative neuroprotective effect of 
both agents. These might include selective pre- and postincubation of cultures with RISP 
or HAL and PAP; comparing the findings on fibroblasts with results on cultures from 
central nervous system that do (eg. neurons) and those do not (eg. glias) express dopamine 
and sigma receptors; and biophysical studies on the direct interaction between these 
antipsychotics and PAP. In light of these evidences, RISP and HAL may be useful leads in 
the development of effective AD therapeutic agents. 
Apart from directly modulating calcium levels and blocking Ca2+-channels, RISP and HAL 
may also alter the metabolism of APP and expression of genes involved in Ca2+-regulation. 
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3. Antipsychotics in the brain - the Alzheimer approach 
3. a. Effect of haloperidol and risperidone on APP metabolism 
Using monoclonal 22C11 antibodies against residues 68-81 of APP, we were able to detect 
wide, APP containing bands at 110-120 kDa (Figures 4, 5). Traditional antipsychotic HAL 
efficiently elevated cortical APP-levels in a concentration-dependent manner (Table VII, 
Figures 4, 6). Significant rise in APP was evident as a result of acute administration of 
HAL in therapeutic and toxic doses within 24 and 12 hours, respectively. Significant 
changes in APP concentrations were between 2-6% when compared to that seen with 
control levels. On the other hand, chronic HAL treatment slightly increased APP 
concentrations, however, did not change APP levels considerably. 
Table VII: Semi-quantitative evaluation of rat cortical APP-Western-blot after 
or without acute and chronic intra-peritoneal HAL administration 
Rat cortical APP-levels were approximated utilizing Western-immuno-blotting. and 
chemi-luminescent visualization of bands were quantified by densitometry. Acute 
HAL-treatment revealed significant increase both in therapeutic and toxic doses 
within 24 and 12 hours, respectively, with regards to APP when compared to that 
seen with control animals. Chronic (1-4-week) administration of HAL resulted in 
incessant APP-levels in SPRD rat cortices in vivo, as detected by chemiluminescent 
Western-blot techniques. Optical densities are depicted in relative units, with the 
controls taken as 100%. (*P<0.05) 
Duration of Control Therapeutic Toxic dose 
treatment dose 
6 hrs 100 101 100.5 
12 hrs 101 103 105.8* 
24 hrs 99.4 107.9* 104.7* 
96 hrs 99.8 103.9* 103.1 
1 week 100 102.8 101.7 
2 weeks 100.5 101.6 102.8 
3 weeks 101 100.4 102.1 
4 weeks 100.3 101.2 101.3 
The atypical antipsychotic risperidone slightly, but not significantly increased cortical APP 
levels in both therapeutic and toxic doses during all treatment periods (Table VIII, Figures 
5, 7). In case of this atypical antipsychotic drug there was neither time-, nor concentration-
dependence with respect to APP levels. 
Table VIII: Time-course of acute and chronic RISP treatment on rat cortical 
APP concentrations 
Semi-quantitative evaluation of cortical APP-Western-blot after or without acute (6, 
12, 24, and 96-hour) and chronic (1-4-week) RISP treatment, administered through 
the intra-peritoneal route, delineates no significant changes both in therapeutic and 
toxic doses with respect to APP when compared to that seen with untreated SPRD 
rats. APP-containing bands were assessed by chemiluminescent Western-
immunoblot techniques, and optical densities are displayed in relative units (controls 
being 100%). 
Duration of Control Therapeutic Toxic dose 
treatment dose 
6 hrs 100 100.8 99.6 
12 hrs 100.4 99.8 101 
24 hrs 100.6 101.1 101.2 
96 hrs 101.2 102.1 102.3 
I week 100 100.8 99.6 
2 weeks 100.4 99.8 101 
3 weeks 100.6 101.1 101.2 
4 weeks 101.2 102.5 102.9 
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Figure 4: APP immunoblots after haloperidol administration in vivo 
Quantification of immunoblot analysis by densitometry delineates A: a marked increase after acute haloperidol treatment. B: Chronic haloperidol reveals no significant changes 
either in therapeutic (Th) or toxic (Tx) doses when compared to that seen with controls (C). 
6 hours | 12 hours | 24 hours | 96 hours 
A I g m , §§§1 | R | ;; I • ' 
C Th Tx C Th Tx C Th Tx C Th Tx 
1 week 2 weeks 3 weeks 4 weeks 
C Th Tx C Th Tx C Th Tx C Th Tx 
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Figure 5: APP immunoblots following risperidone administration in vivo 
Rat cortical APP immunoblots show technically unchanged densities after acute (A) or chronic (B) risperidone treatments, respectively. 
6 hours | 12 hours 24 hours | 96 hours 
A 
C Th Tx C Th Tx C Th Tx C Th Tx 
1 week | 2 weeks | 3 weeks | 4 weeks 
B 
C Th Tx C Th Tx C Th Tx C Th Tx 
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Figure 6: Time-course of HAL on rat cortical APP concentrations 
Intra-peritoneal administration of HAL resulted in significant increase in rat cortical APP-level in therapeutic dose within 24 hours. This elevation was seen even in 12 hours in toxic 
dose of the drug. Both therapeutic and toxic HAL leaved APP concentrations unchanged on the long-run. (F<0.05) 
- - • Control Therapeutic dose Toxic dose 
time 
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Figure 7: Time-course of RISP on rat cortical APP concentrations 
The flow-chart delineates the effect of the typical antipsychotic drug on the APP metabolism in an acute or chronic time-frame. RISP did not significantly interfere with the APP-
levels either in therapeutic or toxic doses. 
- - - Control Therapeutic dose Toxic dose 
time 
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3.a.i. Effect of HAL on APP levels 
Acute administration of HAL apparently yields APP elevation in both therapeutic 
and toxic doses. Because HAL acts as an inhibitor of select proteinases180, 
1 
including secretases that cleave APP , acute HAL leads to increase in the non-
metabolized form of APP. This is supported by the finding that APP metabolism is 
increased by environmental effects that activate Ca2+-signaling pathways44; by 
being a calcium antagonist122, HAL efficiently inhibits APP processing, leading to 
elevated full-length APP levels. 
- Neurotoxicity and neuroprotection 
HAL has been proved to be neurotoxic, and the involvement of oxidative free 
radicals and apoptotic factors is strongly implicated ' 
oi-ligands, such as neurosteroids, play a role in neuroprotection181'182, oi-agonists 
modulate ionotropic, metabotropic and voltage-gated Ca2+-signals, and enhance 
intracellular Ca2+-mobilization . Ca2+ increases APP metabolism in general44, 
| A3 
and also stimulates sAPPa secretion . sAPPa can reduce neuronal cytosolic 
Ca2+-levels and have demonstrated neuroprotective efficacy against a variety of 
insults84. Moreover, oi-receptor agonists play an important role in learning and 
memory. They have been demonstrated to possess neuromodulatory effects; they 
potentiate cholinergic neurotransmission and the glutamatergic system185'186. Also, 
neuroprotection against PAP-induced neurotoxicty was reported187. Because the 
traditional neuroleptic HAL acts as sigma oi-antagonist119, it inhibits this complex 
neuroprotective pathway to yield sAPPa, and therefore increases full-length APP 
levels. 
By being a D2-receptor antagonist118, HAL decreases PKC activity and level188. 
Activating PKC would lead to secretion of neuroprotective sAPPa189'190, and to 
Modulation of Ca2+-currents by regulating Ca2+-channels through second 
messengers ' 
Ca2+, one of the most important second messengers in the brain, 
decreases APP mRNA levels193. Taken together, decreased PKC by HAL 
increases APP mRNA. 
Even though increased APP level is a precondition to excessive neurotoxic pAP 
formation, one of the inducible neuroactive (trophic) factors at site of neural 
injury is the APP that may participate in cell-to-cell recognition, re-establishment 
of synaptic contacts, alleviation of glutamate-induced membrane depolarization 
and over-excitation, and stabilization of the intracellular Ca2+ 
homeostasis164'181'194'195. Therefore, it is assumed that APP is an important protein 
for tissue repair and that its expression is upregulated following nerve damage196, 
as might be expected to occur following amyloid fibril formation or 
administration of toxic agents, such as HAL. In addition, persistent induction of 
APP expression without subsequent accumulation of PAP in response to acute 
brain injury substantiates the neuroprotective potential of APP19 '197. This may 
account for the elevated APP level seen in these experiments after HAL treatment. 
Because HAL is neurotoxic, acute increase in APP after HAL-treatment might be 
considered as such a compensatory mechanism. This is supported by the 
observation that the presumably non-toxic RISP does not exert such effects. 
Further hypothesizing the advantageous roles of HAL, elevated APP levels might 
be a preconditioning effect of HAL to other nocuous agents, such as PAP. 
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Moreover, HAL is known to increase the activity of NF-KB198. Activation of NF-
KB by either sAPPa199 or HAL stabilizes cellular Ca2+ homeostasis by modulating 
the expression of genes that encode Ca -binding proteins, ionotropic glutamate 
receptor subunits, and anti-apoptotic bcl-2 family members200. This is in line with 
HAL-induced cellular protection with respect to neurotoxic APP metabolites, ie. 
PAP, in peripheral tissues (Table V). 
-HAL and Co2* in AD 
Abnormal signal transduction systems have been implicated in the 
pathophysiology of AD and in APP metabolism, but their precise role has been 
difficult to establish. It is therefore reasonable to hypothesize that the action of 
HAL on APP processing is a fine-tuning mechanism involving various second 
messengers, such as Ca2+. 
Calcium, as discussed above, plays central role in HAL-induced neurotoxicity and 
neuroprotection both in general and in AD. However, HAL modulates 
extracellular Ca2+-influx and intracellular Ca2+-mobilization through oi-receptors, 
therefore stabilizes Ca2+. This fine-tuning mechanism leads to constitutive sAPPa 
secretion, which precludes pAP formation. This is in line with the finding on 
peripheral cells that HAL attenuates pAP-induced Ca2+-imbalance and stabilizes 
[Ca +]i (Table V). Moreover, because it has been shown to non-selectively block 
Ca2+-channels122, HAL 
may also directly protect in AD against pores formed in 
the membrane by pAP that act as cation (eg. Ca2+) channels 9. 
Yielding an elevated APP concentration in the aforementioned Ca2+-dependent 
manner by HAL is two-fold: suppressing its cleavage or elevating IIIRNAAPP-
level. HAL has been reported to block the amyloidogenic processing of APP, 
which, in turn, precludes PAP production123, and therefore may stimulate 
neuroprotective sAPPa secretion which may attenuate both self-induced (ie. direct 
toxicity of HAL) and PAP-derived neurotoxicity. 
Nevertheless, chronic treatment with HAL results in stable APP levels, which 
leads to decreased deposition of PAP in the brain over time by inhibiting PAP 
formation123 and alleviating PAP-induced toxicity as presented above. When 
previous reports are taken together with our findings, the impact of HAL in AD is 
3-fold: it stabilizes Ca2+, stimulates sAPPa secretion and inhibits pAP formation; 
these effects are inter-connected. This may further confirm why a low frequency 
of AD is present in SCH patients, as many of them are likely to have been treated 
chronically with antipsychotics, including HAL. 
- APP-receptor 
Various ligand-operated ion channels that control intracellular Ca2+-levels may 
also regulate APP processing44. Both sAPPa and PAP have been demonstrated to 
modulate cytoplasmic Ca2+ concentration43,84, raising the possibility that these 
compounds may regulate their own formation. This fine-tuning mechanism may 
be characteristic of AD because of the involvement of various APP-related 
substances. However, by being a putative cell-surface receptor, APP itself might 
also be directly involved in this scenario68. APP might be a single metabotropic 
receptor coupled to GTP-binding proteins201201, or it may be a part of a larger 
receptor complex potentiating D2- and/or oi-receptors. Elevated APP levels after 
acute HAL treatment argue for this hypothesis, in that inhibitory ligands (eg. 
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HAL) result in compensatory up-regulation of their receptors (eg. APP itself). 
Therefore, HAL-APP receptor-kinetics should be investigated in the future. 
3. a. ii. Effect ofRISP on APP levels 
Atypical RISP has common action with HAL on D2-receptors. However, it also acts 
as serotonergic-antagonist, of which 5-HT2 and 5HT4-receptors have been shown to 
stimulate sAPPa secretion202. Moreover, lesions of cholinergic, serotonergic, and 
adrenergic neurotransmitter systems all result in the induction of APP levels203. By 
antagonizing both 5-HT and NA (ie. adrenergic) receptors, slight elevation in APP 
concentration elicited by RISP treatment is apparently evident. This suggests that 
RISP may induce neuroprotection against various internal or external nocuous 
stimuli by slightly stimulating APP expression164'194,197. Furthermore, considering 
that increase in APP level is seen after exposition to potentially toxic agents (eg. 
HAL), marked elevation in APP concentration is not present after treatment with 
the presumably non-toxic RISP. 
In contrast with HAL, high potential atypical antipsychotic RISP did not have a 
significant effect on APP, nor does the literature have any information on its 
importance at any level in AD, be it clinical or molecular. The observed changes 
elicited by HAL are therefore better explained. Even though both drugs act as D2-
antagonists, involvement of oi-receptors, altered affinity to APP, direct 
cytotoxicity, or other unknown mechanisms may account for the differing impact of 
HAL from RISP on APP metabolism. However, the slight increase in APP levels as 
a result of RISP treatment (Figure 7) might also be regulated by gordian 
mechanisms; apart from D2-receptors, the involvement of numerous factors beyond 
the first messenger level along with 5-HT2 and NA-receptors, and above all Ca2+, 
might be implicated. 
3.a.iii. Implication in AD 
The pharmacological actions of HAL and RISP are important in the course of 
dementia. Antipsychotics did not affect intracellular Ca2+ levels in AD fibroblasts 
in the presence or absence of PAP treatment. In case of APP, however, their 
molecular impact is crucial in AD. 
The major route of APP processing is via a-secretion, in which APP is cleaved by 
a-secretase at or adjacent to Lysi6 in the PAP sequence77 (Figures 1, 2). This route 
of processing has two important consequences. On one hand, C-terminally 
truncated form of APP (ie. sAPPa) is released from the membrane and can be 
subsequently secreted from the cell. Also, this pathway destroys the complete pAP 
sequence and therefore may mitigate amyloid formation. The amyloidogenic APP 
metabolic route produces PAP via the activation of P~ and y-secretases. 
Intact cellular homeostasis, including relatively stable Ca2+-level, leads to 
constitutive sAPPa-secretion. Because sAPPa is known to stabilize cytosolic Ca2+-
dynamics, normal processing of APP stimulates sAPPa production. Because HAL 
and also probably RISP stabilize Ca2+, a protective circle is proposed in this thesis. 
By producing relatively constant Ca2+ concentrations, HAL and RISP stimulate 
sAPPa formation, which in turn stabilizes Ca2+ levels. Apart from constitutively 
secreted sAPPa, receptor-activated sAPPa release mediated by protein kinases -
such as PKC - is a crucial pathway in APP metabolism204'205. As discussed above, 
activated PLC affects APP processing by either of two pathways, one involving an 
increase in PKC (PLC-DAG-PKC cascade) and the other an elevation in 
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cytoplasmic Ca2+-levels (PLC-IP3-Ca2+ limb of the pathway). Both pathways, 
probably also activated by HAL and RISP, are known to stimulate sAPPa 
production and inhibit PAP formation204. 
Unlike usual conditions, however, cells in AD are exposed to neurotoxic PAP. The 
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PAP-limb of the APP pathway has been shown to induce significantly altered Ca 
levels both in this thesis and elsewhere. Increased or decreased levels of 
cytoplasmic Ca24 plays a role in the abnormal proteolytic processing of APP 
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resulting in increased PAP formation ' . This feed-forward neurodegenerative 
pathway leads to cell death by sustained Ca2-levels and inhibited sAPPa secretion. 
By antagonizing pAP-induced Ca24-imbalance, stabilizing Ca24-levels, and 
inhibiting PAP formation, the protective circles of HAL and RISP are important 
events in slowing the progression of AD. 
Protein kinases, such as PKC, are involved in receptor-mediated sAPPa production. 
These protein kinases can be activated by second messengers, such as Ca24, or in 
turn, these kinases may activate second messengers, including Ca2+. Even though 
Ca2t-cascade can regulate APP metabolism in a PKC-independent fashion, 
hyperactivation of kinases by incessant Ca2-imbalance can activate PKC-reliant 
amyloidogenic APP processing. 
Because propeptides of P- and y-secretases undergo phosphorylation in order to 
yield active proteases208, PKC-mediated phosphorylation plays a critical role in the 
regulation of sAPPa and PAP secretion, and PKC-mediated pathways may help 
control amyloid formation. However, PKC appears to mediate APP secretory 
processing not directly but via additional intracellular messengers. Apart from Ca2+, 
one reasonable candidate for the phosphoacceptor is the APP secretase itself. In the 
course of the disease, "mal-activation" of kinases leads to hyper-phosphorylation, 
which may stimulate not only amyloidogenic APP processing, but also hyper-
phosphorylation of the axonal transport-associated protein tau, which ultimately 
yields PHF. By acting on Ca2+, both HAL and RISP are proposed to alleviate these 
effects seen in AD. 
Taken together, PAP-Ca2+ feed-forward (Figure 8) and sAPPa-Ca2+ feed-back, ie. 
"protective circle" of HAL (Figure 9) is proposed in AD. 
Figure 8: Proposed PAP-Ca2+ feed-forward 
a-secretas fyj^ ^ y p/y-secretase —— Ca2+f 
PAP 
sAPPa HAL 
+ 
RISP 
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Figure 9: Proposed sAPPa-Ca2+ feed-back - "protective circle" of HAL 
HAL 
+ 
RISP 
stable Ca2+- a-secretase / /y-secretase 
pAP 
• • • • I 
sAPPa 
Gene expression profile of antipsychotics in the brain 
It has been shown in this study that HAL and RISP interfere with Ca2t and APP 
metabolism in AD. It is not yet fully understood whether this is a direct interaction taking 
place at the proteomic level, or their exact mode of action is interfering with genes and 
their expression - or perhaps both. 
Recent advances in high-density cDNA microarray technique allow the possibility to 
analyze thousands of genes simultaneously for their differential gene expression patterns in 
various biologic processes, and determining mechanisms of drug action. The aim of this 
series of experiments was to gain experience in antipsychotic gene-expression profiling 
and characterize (in the parlance of genomics) the "antipsychotic transcriptome." 
An important step to understanding the role of genes in the mechanism of drug action is to 
define gene expression profiles after drug manipulation. DNA expression array technology 
can monitor the expression of thousands of genes simultaneously and provide a format for 
identifying genes209. DNA microarrays allow genome-wide assessment of changes in 
relative messenger RNA abundance and thus can be used to monitor changes in gene 
expression as a result of various medications. Using this novel method we determined the 
effect of acute and chronic effect of HAL and RISP on the expression of approximately 
8,000 gene targets in rat prefrontal/fronto-parieto-temporal cortex (Figure 10). This region 
of brain was chosen because this is an area in which abnormalities have been reported in 
SCH patients, where dopaminergic neurons largely project, and where antipsychotics have 
been shown to have numerous effects. Moreover, this is the area where AD-specific 
changes occur, and where HAL and RISP were shown in this study to have beneficial 
effects in dementia. 
This study is very important, since the pharmacotherapy of psychiatric drugs continues to 
be based on trial and error, with psychiatric diagnosis serving as the principle guide for 
drug choice. Often drug selection within a therapeutic category (eg. antipsychotic) is based 
on side-effect profile (eg. sedation) to match a clinical need. Therapeutic response, even 
among diagnostically homogenous patient groups, is highly variable within classes of 
psychiatric drugs. Until now, little information is available on the molecular effect of 
antipsychotics. 
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Figure 10: cDNA microarravs 
Gene-chips hybridized with Cy5 labeled cDNA probe (obtained from untreated rat cortical 
total RNA) and Cy3 labeled cDNA probe (obtained from antipsychotic-treated cortical total 
RNA) 
3. b. i. A nalysis of DNA -chips 
A number of transcripts were differentially expressed between control and treated 
samples. However, among the 8,000 genes examined in the present study the 
expression of only 36 genes (0.45%) was found to be significantly altered after 
treatment with HAL. In case of acute administration of HAL, 13 genes were more 
highly expressed and 15 transcripts were found to be significantly less abundant. 
After chronic HAL treatment, however, 9 transcripts were induced and none of 
them was considerably repressed. 
The list of genes with significantly altered expression (P<0.05) is delineated in 
Tables IX-X. Values are presented as the expression ratio of treated / untreated 
cases for a certain gene. Apart from these known transcripts, a number of expressed 
sequence tags (ESTs) with unknown function were also differentially expressed in 
the antipsychotic-treated cortices; these are not listed. 
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Table IX: List of differentially expressed genes in rat fronto-temporo-parietal cortex 
after acute (96 hours) treatment with HAL. A: over-expressed, and B: repressed 
genes 
A : 
Clone name A Fold Accession Functional group 
(mRNA) (mean) number 
Follistatin-like protein 1.09 AA818445 Cell cycle and growth 
Rat basic fibroblast growth factor (FGF) 
mRNA, complete cds 1.19 M22427 
Cell cycle and growth 
Protein O-mannosyltransferase 1 1.15 NM 053406 Development 
Rattus norvegicus cDNA clone, similar 
to Human B12 protein mRNA 1.96 AA900186 
Ion transport 
S100 calcium-binding protein A8 
(calgranulin A) (S100A8) 1.41 NM 053822 
Ion transport 
Glutamate receptor subunit GIuR2-flip 
mRNA, complete cds 1.22 AFI64344 
Ion transport 
Calmodulin 2, mRNA, complete cds 1.13 BC058485 Ion transport 
Glutathione S-transferase A5 (Gsta5), Metabolism 
mRNA 1.19 NM 031509 
Rattus norvegicus similar to eosinophil 
peroxidase (LOC303414), 
mRNA 1.21 XM 220834 
Metabolism 
Adrenal mitochondrial protease 1.97 NM 153311 Protein metabolism 
G protein-binding protein CRFG 1.06 NM 053689 Signal transduction 
Ly-49 stimulatory receptor 3 1.20 NM 153726 Signal transduction 
Rattus norvegicus APP770 mRNA, 
complete cds 1.76 AF513015 
Other 
B: 
Clone name A Fold Accession Functional group 
(mRNA) (mean) number 
Pleiotrophin (heparine binding factor) -1.11 NM 017066 Cell cycle and growth 
Serotonin N-acetyltransferase -2.15 NM 012818 Circadian rhythm 
Activity regulated cytoskeletal-
associated protein -1.99 NM 019361 
Development 
a-prothymosin -1.48 M86564 Immune response 
Inwardly rectifying K'-channel -1.89 D61687 Ion transport 
Voltage-dependent calcium channel y-7 
subunit (Cacng7) mRNA, 
complete cds -1.21 AF361349 
Ion transport 
Tyrosine aminotransferase -2.68 NM 012668 Metabolism 
Rattus norvegicus mRNA for 
endothelial nitric oxide synthase, 
Metabolism 
3' region, partial -1.57 AJ011116 
Clathrin assembly protein long form -1.04 AF041374 Protein metabolism 
SH3 domain binding protein (CR16) -1.82 U25281 Protein metabolism 
Disintegrin and metalloprotease domain 
2 -2.15 NM 020077 
Protein metabolism 
MIBP1 (c-myc intron-binding protein 1) -0.99 D37951 Transcription regulator 
Gap junction membrane channel p5 -1.24 NM 019241 Cell-cell interaction 
Type I pro-cb collagen-like sequence -3.25 AF050214 Other 
TPCR09 protein -2.07 X89698 Other 
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Table X: List of differentially expressed genes in rat fronto-temporo-parietal cortex after 
chronic (4 weeks) treatment with HAL 
Clone name A Fold Accession Functional group 
(mRNA) (mean) number 
Follistatin-like protein 1.58 AA818445 Cell cycle and growth 
Transducin-like enhancer of split 4 1.51 NM 019141 Development 
iC-channel (erg2) 1.11 AF016192 Ion transport 
Acyl-Coenzyme A dehydrogenase, C-4-
12 0.97 NM 016986 
Metabolism 
Extracellular signal-related kinase 
(ERK.2) 1.02 M64300 
Signal transduction 
G protein-binding protein CRFG 1.31 NM 053689 Signal transduction 
Relaxin-like factor 1.37 AF139918 Signal transduction 
Endothelin receptor 1.69 NM 017333 Signal transduction 
U2 RNA 3' end 1.59 Ml 0882 Others 
In case of RISP, 89 genes ( 1 . 1 1%) were found to significantly differ in expression. 
Acutely, 43 genes were induced and 46 were down-regulated (Table XI). 
Chronically, however, this number has decreased to 6 and 1 1 , respectively (Table 
XII). 
3. b. ii. Verification by QRT-PCR 
To validate these semi-quantitative results, the expression of randomly selected 7 
genes was analyzed by real-time quantitative PCR (QRT-PCR). The PCR primers 
used in this study are listed in Table XIII. The results for each sample were 
normalized to |3-actin expression, then subjected to t-test analysis. All 7 transcripts 
were still identified as significantly more or less abundant, or unchanged, 
respectively (Figure 11). Comparison of the results derived from microarraying and 
the more accurate real-time PCR showed a qualitative agreement in that the 
differentially expressed genes in HAL or RISP-treated cortices were correctly 
assigned as up- or down-regulated, or significantly unchanged. 
3.b.iii. Significance of genes with altered expression 
In this study, we utilized the high-throughput gene chip, which contains 8,000 
known genes and ESTs, to determine the alteration of gene expression profiles of 
rat cortex exposed to antipsychotics. Our results from microarray provided a 
genome-wide analysis of the cellular response to HAL and RISP treatment: 
- Neural plasticity 
Cellular and molecular responses of neurons to antipsychotic treatment are 
complex and are likely to be mediated by a variety of regulatory pathways. We 
found that the molecular response to these drugs in rat cortex involved inhibition 
or induction of genes, which have specific functions in signal transduction, 
transcriptional and translational regulation, protein turnover, and cellular 
metabolism (Tables IX-XII). All of these pathways are inevitable factors of 
neuronal plasticity. One of the central elements of this process is the activation of 
glutamatergic transmission. 
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Table XI: List of significantly A: induced, and B: down-regulated genes in rat fronto-
temporo-parietal cortex after acute (96 hours) treatment with RISP 
A: 
Clone name A Fold Accession Functional group 
(mRNA) (mean) number 
Inteerin a-subunit 1.13 S58528 Cell adhesion 
Integrin P, 1.70 NM 017022 Cell adhesion 
Plakoelobin 2.20 U58858 Cell adhesion 
Pleiotrophin (heparine binding factor) 1.11 NM 017066 Cell cycle and growth 
KIAAI536 protein 1.28 NM 139190 Cell cycle and growth 
Follistatin-like protein 1.96 AA818445 Cell cycle and growth 
Protein O-mannosyltransferase 1 1.57 NM 053406 Development 
HES-related repressor protein 1 
(HERP1) 1.00 AY059382 
Development 
RING finger protein 2.07 AF036255 Development 
Transducin-like enhancer of split 4 1.52 NM 019141 Development 
Transmembrane receptor Robol 1.71 AF041082 Development 
T-cell receptor a-chain RT1L haplotype 1.57 LI 1027 Immune response 
Small inducible cytokine subfamily A20 2.31 NM 019233 Immune response 
Synaptotagmin VII 1.62 U20I06 Protein metabolism 
RAB 15 2.24 M83679 Protein metabolism 
/^¿-tyrosine kinase-related protein 2.67 AB073721 Protein metabolism 
Janus protein tyrosine kinase 1, JAKI 1.48 AJ000556 Protein metabolism 
YME1 (S. cerevisiae)-like 1 1.14 NM 053682 Protein metabolism 
Aminopeptidase PILS 1.15 AF148324 Protein metabolism 
Adrenal mitochondrial protease 1.47 NM 153311 Protein metabolism 
Cathepsin K 1.89 AF010306 Protein metabolism 
CLN2 tripeptidyl peptidase I 2.35 AB043870 Protein metabolism 
Similar to Human B12 protein 1.77 AA900186 Ion transport 
lO-channel (erg2) 2.08 AF0I6192 Ion transport 
Na"-channel, voltage-gated, type 10a 1.01 NM 017247 Ion transport 
Vacuolar adenosine triphosphatase-p 1.40 Y12635 Ion transport 
ATPase, Na+/K+ transporting, at 2.00 NM 012504 Ion transport 
Acyl-Coenzyme A dehydrogenase, C-4-
12 2.13 NM 016986 
Metabolism 
Kruppel-like factor LKLF 1.92 AA925780 Transcription regulator 
Prophet of Pit 1, paired-like 
homeodomain 1.96 NM 153627 
Transcription regulator 
Activating transcription factor 3 2.50 NM 012912 Transcription regulator 
Splicing factor 1 homolog 1.75 AF079873 Signal transduction 
SH-PTP2 protein tyrosine phosphatase 
11 2.74 NM 013088 
Signal transduction 
Receptor activity modifying protein 2 1.00 AB042888 Signal transduction 
Interleukin 6 receptor 3.12 NM 017020 Signal transduction 
G protein-binding protein CRFG 1.89 NM 053689 Signal transduction 
Endothelin receptor 2.04 NM 017333 Signal transduction 
P-glycoprotein-like ATP cassette 
transporter 1.02 AFI 06563 
Transport 
Mgl 1.48 AY035343 Others 
FSH-regulated protein 1.71 L26292 Others 
Integrin-binding sialoprotein 2.14 NM 012587 Others 
Ly-49 stimulatory receptor 3 1.84 NM 153726 Others 
Neurexin Ilia (axon guidance) 2.84 LI4851 Others 
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B: 
Clone name A Fold Accession Functional group 
(mRNA) (mean) number 
Neural adhesion molecule F3 -1.37 D38492 Cell adhesion 
BIT -1.12 D38468 Cell adhesion 
CD5 -2.60 X78985 Cell adhesion 
Growth accentuating protein 43 -1.01 NM 017195 Cell cycle and growth 
Serotonin N-acetyltransferase -1.31 NM 012818 Circadian rhythm 
Activity regulated cytoskeletal-
associated protein -2.31 NM 019361 
Development 
a-actinin 4 -1.19 AFI90909 Development 
Protein phosphatase 1, regulatory 14a -2.61 NM 130403 Immune response 
a-prothymosin -1.62 M86564 Immune response 
EFA6 exchange factor for ARF6 -1.40 AB040468 Protein metabolism 
ARL5 ARF-like protein 5 -1.31 X78604 Protein metabolism 
Ubiquitin C (Ubc) -1.54 NM 017314 Protein metabolism 
Clathrin assembly protein long form -1.61 AF041374 Protein metabolism 
SH3 domain binding protein (CR16) -1.59 U25281 Protein metabolism 
Hippocalcin (Hpca) -1.63 NM 017122 Protein metabolism 
Disintegrin and metalloprotease domain 
2 -2.15 NM 020077 
Protein metabolism 
Disintegrin and metal loproteinase 
domain 1 -1.09 NM 020078 
Protein metabolism 
Voltage-dependent calcium channel g8 -2.21 NM 080696 Ion transport 
Plasma membrane CA~"-ATPase 3 -1.47 M96626 Ion transport 
Inwardly rectifying KT-channel -2.32 D61687 Ion transport 
Mitochondrial Ff-ATP synthase-a -1.16 J05266 Ion transport 
Uncoupling protein 2, mitochondrial -1.53 NM 019354 Ion transport 
Alkaline phosphatase, tissue-nonspecific -1.17 NM 013059 Metabolism 
Tyrosine aminotransferase -1.52 NM 012668 Metabolism 
y-glutamylcysteine synthetase -2.12 NM 017305 Metabolism 
MIBPI (c-myc intron binding protein 1) -1.13 D37951 Transcription regulator 
Extracellular signal-related kinase Signal transduction 
(ERK.2) -1.95 M64300 
Interleukin lOreceptor-a -2.68 NM 057193 Signal transduction 
Basignin (0x47 antigen or CE-9) -2.02 NM 012783 Signal transduction 
Relaxin-like factor -1.95 AF139918 Signal transduction 
Soluble adenylyl cyclase (SAC) -2.37 AF081941 Transport 
Messenger RNA for preproalbumin -1.17 V01222 Transport 
Vesicular GABA transporter -1.41 AF030253 Transport 
gcd-1 OS -1.17 AB046592 Transport 
Gap junction membrane channel 05 -1.11 NM 019241 Cell-cell interaction 
Type I pro-a2 collagen-like sequence -3.77 AF050214 Others 
Putative zinc-finger protein -3.40 AJ007467 Others 
U2 RNA 3' end -2.63 M10882 Others 
Glucagon (Gcg) -2.17 NM 012707 Others 
LIM homeodomain protein 30 -1.61 AF370447 Others 
Limkain 01 (Lkap) -1.38 NM 133421 Others 
mud-2 -1.28 U70266 Others 
Zinc finger protein 2 (DZF2) -1.11 U78130 Others 
Axomer-8. transported in axons -1.00 AB097858 Others 
DnaJ-like protein (heat shock response) -1.15 U53922 Others 
TPCR09 protein -1.21 X89698 Others 
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Table XII: List of significantly A: up-regulated, and B: repressed genes in rat fronto-
temporo-parietal cortex after chronic (4 weeks) treatment with RISP 
A: 
Clone name A Fold Accession Functional group 
(mRNA) (mean) number 
Follistatin-like protein 1.09 AA818445 Cell cycle and growth 
Protein phosphatase 1, regulatory 14a 2.30 NM 130403 Immune response 
Acyl-Coenzyme A dehydrogenase. C-4-
12 1.24 NM 016986 
Metabolism 
Prophet of Pitl, paired-like 
homeodomain 1.69 NM 153627 
Transcription regulator 
Extracellular signal-related kinase Signal transduction 
(ERK.2) 1.35 M64300 
Receptor activity modifying protein 2 3.35 AB042888 Signal transduction 
B: 
Clone name A Fold Accession Functional group 
(mRNA) (mean) number 
EFA6 exchange factor for ARF6 -1.04 AB040468 Protein metabolism 
Clathrin assembly protein long form -1.49 AF041374 Protein metabolism 
Janus protein tyrosine kinase 1, JAKI -1.37 AJ000556 Protein metabolism 
Inwardly rectifying Kf-channel -1.65 D61687 Ion transport 
Uncoupling protein 2, mitochondrial -1.25 NM 019354 Ion transport 
Alkaline phosphatase, tissue-nonspecific -1.67 NM 013059 Metabolism 
Endothelin receptor -1.03 NM 017333 Signal transduction 
P-glycoprotein-like ATP cassette 
transporter -1.13 AF106563 
Transport 
U2 RNA 3' end -1.56 M10882 Others 
Limkain (31 (Lkap) -1.16 NM 133421 Others 
TPCR09 protein -0.91 X89698 Others 
HAL has been proved to mediate glutamate transmission by interfering with the 
expression of NMDA-receptor subunits 2 10 and glutamate transporters 2 1 1 . 
Glutamatergic transmission at either the N-methyl-D-aspartate (NMDA) or a-
amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors is one 
mechanism for an increase in synaptic strength and the induction of central 
sensitization212. Activation of these ionotropic receptors causes a sustained 
elevation in postsynaptic Ca2+ that induces a cascade of persistent intracellular 
events contributing to synaptic plasticity212213. Therefore, by acting on the 
glutamatergic system (eg. glutamate receptor subunit GluR2-flip), both HAL and 
RISP mediate Ca2+-permeability of cells, and therefore mediates synaptic 
plasticity. 
From the gene expression profiles of rat cortices exposed to HAL and RISP, it 
was also found that many genes are related to cell cycle control. Moreover, we 
also observed altered expression of genes encoding kinases including extracellular 
signal-related kinase (ERK2), ryA>tyrosine kinase-related protein, Janus protein 
tyrosine kinase 1, growth factors (eg. follistatin-like protein, basic fibroblast 
growth factor, pleiotrophin), and transcription factors, suggesting that HAL and 
RISP may also influence cell growth via mediation of multiple cell signal 
transduction pathways. These results confirm and provide mechanistic 
information about HAL- and RISP-induced neuro-plasticity. 
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Table XIII: Primers used in QRT-PCR analysis 
Gene product Forward primer Reverse primer 
Serotonin N-acetyltransferase ACCGCTTGCCTTCTGAACA CCCGCTGCTCCCGTTT 
Follistatin-like protein TTTCGTGTATGGCATCAACCA GCGTCCAATTCCCAAGGA 
Inwardly rectifying K+-channel AGTGTGGCTGTGGCAAAGG CCGCAACTCAGGACAAGGA 
Guanine nucleotide regulatory protein CCAGCCTGGCTCCTCAGA TGTTGCAGTCTCGAATTAGCTTCT 
Endothelial nitric oxide synthase AATAAATTCCCCTTCACGACCTT CCTGCGGCTGCATCAATAT 
Clathrin assembly protein long form GATTCTGGTGGTGGACTTCTCAA GGCGGAAGTTTGGCAACA 
Rattus norvegicus cDNA clone GGCCCAGAATGATGAGCAA TGATTGGCGGCGTCGTA 
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Figure 11: Quantitative determination of transcript levels by real time PCR 
Changes in transcript levels in rat ffonto-temporo-parietal cortex after acute or chronic intraperitoneal treatment with HAL (light and dark green box, respectively) or R1SP (light and 
dark blue box, respectively) were confirmed by real time PCR (dashed light and dark green box for HAL, respectively; and dashed light and dark blue box for RISP, respectively). 
The expression of serotonin-N-acetyltransferase, follistatin-like protein, inwardly rectifying K+-channel, guanine nucleotide regulatory protein, endothelial nitric oxide synthase, 
clathrin assembly protein, and a Rattus norvegicus cDNA clone was determined. Dashed lines indicate the interval -1.8 to 1.8-fold regulation (corresponding to logj = 0.85) in which 
changes in expression were considered not significant. 
Serotonin-N-
acetyltransferase 
Follistatin-like protein Inwardly rectifying 
potassium channel 
Guanine nucleotide 
regulatory protein 
Endothelial nitric oxide 
synthase 
Clathrin assembly 
protein 
Rattus norvegicus cDNA 
clone 
• 96hr H A L ( c D N A chip) 
• 96hr RISP (cDNA chip) 
• 96hr HAL (QRT-PCR) 
a 96hr RISP (QRT-PCR) 
I 4wk HAL (cDNA chip) 
I 4wk RISP (cDNA chip) 
14wk H A L (QRT-PCR) 
I 4wk RISP (QRT-PCR) 
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- Role in neurometabolic disorders 
The results of our analysis implicate on the order of hundreds of genes as being 
involved in neurodegenerative diseases. 
Several genes directly related to Ca2+ homeostasis were found to be differentially 
regulated by HAL and RISP, eg. SI00 calcium-binding protein A8, calmodulin 2, 
voltage-dependent calcium channel y-7 subunit, plasma membrane CA2+-ATPase 
3, etc. (Tables IX-XII). We have reported alterations of calcium homeostasis in 
neurometabolic conditions and other medical disorders in the present study. We 
have also shown that HAL and RISP are efficient in stabilizing [Ca2+]i, and 
therefore have a protective role in AD and various neuropsychiatric disorders. 
However, their mechanisms of action remained unknown. Broadly in line with the 
present findings on gene expression, the Ca2+-stabilizing beneficial effects of 
these antipsychotics are based on the genomic level by interfering with Ca2+-
transporters, Ca2+-channels, glutamatergic transmission, etc. (Tables IX-XII). 
We have also reported above that HAL up-regulates the level of APP, a key 
precursor molecule in AD that yields neurotoxic PAP. Interestingly however, as 
aforementioned, APP might play a crucial role in neuroprotection by participating 
in cell-to-cell recognition, re-establishment of synaptic contacts, alleviation of 
glutamate-induced membrane depolarization and over-excitation, and stabilization 
of the intracellular Ca2+ homeostasis164'194. HAL therefore may stimulate 
cytoprotective pathways by inducing APP gene expression, as presented here and 
above. However, the direct neurotoxic effect of HAL118"121 may also account for 
the elevated APP level as a defensive response seen in our experiments after HAL 
treatment. 
The finding that HAL increases APP protein level, as discussed above, is now 
better explained, in that it is demonstrated here for the first time that HAL up-
regulates APP mRNA. Ca2+ has been proposed to modify the production and 
processing of APP44. By acting on Ca2+-homeostasis, as we have presented above 
and herewith, HAL may also indirectly interfere with APP both at the genetic and 
at the proteome level. 
Because of its fundamental roles in regulating synaptic transmission, plasticity, 
and cell survival, Ca2+ homeostasis is undoubtedly altered, at some point in the 
pathogenesis of AD. The research described here suggests that altered Ca2+-
regulation contributes greatly to the pathogenic effects seen in neuropsychiatric 
conditions. Therefore, targeting Ca2+ for potential therapies is therefore worth 
consideration. 
It is proposed in this study that relatively stable levels (ie. slight oscillations) of 
Ca2+ leads to normal or non-amyloidogenic APP processing (sAPPa-Ca2+ feed 
back, Figure 9), whereas pathological increase or decrease in Ca2+ triggers 
amyloidogenic APP metabolism (PAP-Ca2+ feed forward cascade, Figure 8), as 
discussed in this study. This provides a fine tuning mechanism in APP regulation. 
Both sAPPa and PAP have been demonstrated to modulate cytoplasmic Ca2+ 
concentration43'84, raising the possibility that these compounds may regulate their 
own formation. Also, the biphasic regulation in AD fibroblasts presented in this 
thesis is well established. PAP results in aberrant regulation of [Ca2+]j such that 
there is an enhancement of acute activation (ie. elevated levels), followed by a 
sustained depression of Ca2+-concentration and signaling, when cells are exposed 
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to PAP and other insults214. Subtle alterations in this metabolic balance over a 
long period of time are likely to influence cellular homeostasis, be it proteomic, 
ionic, genetic, or other. Therefore, Ca2+-stabilizing interventions should be 
considered the foundation of treating dementing neurodegenerative conditions. 
Because abnormalities in Ca2+ homeostasis are also present in psychosis215,216s217 
and depression218'219, both associated with AD, this study points out that these 
psychiatric disturbances manifest in dementia because of the Ca2+-imbalance 
present in the primary disease. It is not difficult to see how disruption of a single 
interaction (ie. Ca2+ dysregulation) can have multiple flow-on effects to other 
cellular processes. Based on the protective role of antipsychotics regarding Ca2+-
imbalance, antipsychotics may constitute future treatment strategies aimed at 
alleviating BPSD and the cognitive symptomatology of AD. The use of 
antipsychotic drugs to treat dementia and co-morbidities associated with AD is 
apparently justified at the molecular level with respect to Ca2+. 
The involvement of Ca2+ has been implicated in neurometabolic disorders other 
than AD and its corollary symptoms, such as in Parkinson's220, Huntington's221, 
amyotropic lateral sclerosis , SCH215"217, muscular dystrophy223, etc., suggesting 
a broad-spectral role of Ca2+ in neuropsychiatric disorders. A great number of 
articles were devoted to Ca2+ in brain physiology and pathology, but literally no 
paper has ever studied the role for Ca2+ at the holistic level. Broadly in line with 
the above findings, this study proposes that disturbing the central secondary 
messenger, Ca2+, plays pivotal roles in various, if not all neurometabolic 
disorders. Impaired Ca2+ homeostasis has different functional consequences that 
mainly involve mechanisms to compensate Ca2+ imbalance. Environmental and 
genetic factors may determine that these functional compensatory mechanisms 
involve which of the many tertiary and quaternary messenger systems, yielding 
differing brain pathology, ie. altered Ca2+ leads to P-amyloid deposition in 
Alzheimer's, a-synucleinopathy in Parkinson's, accumulation of Lewy bodies, 
etc. This is supported by the existence of overlapping disorders (eg. AD with 
Lewy-bodies) and frequent co-morbid conditions (eg. depression in most 
neuropsychiatric maladies), as described earlier. 
CJ I 
The central role of Ca in various diseases of the man is signified not only in 
neuropsychiatric disorders, but also in many medical conditions. Ca2+-channel 
blockers, for example, in arrhythmias, cardiac failure and hypertension, have 
proved to efficiently restore Ca2+ homeostasis. Moreover, Ca2+-channel blockers 
were reported to limit cellular degeneration224. This thesis, therefore, proposes a 
new approach to Ca2+ imbalance at the holistic level (Figure 12). 
Therefore, stabilizing calcium levels with Ca2+-channel blockers, calmodulin 
antagonists, etc. may slow or inhibit the progression of and may reverse several 
neurometabolic disorders, and conditions afflicting other organs, too. 
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Figure 12: Proposed central role of Ca2+ in (neurometabolic) diseases 
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- Stress and neurotoxicity 
Documented consequences of HAL treatment are neurotoxicity and apoptosis118" 
121, which apparently may be attributable to its impact on the central secondary 
messenger, Ca2+. Despite its molecular and clinical adverse effects, HAL is 
widely used in the treatment of psychiatric symptoms associated with various 
medical conditions where the involvement of Ca2+ is implicated, such as in AD. 
Interestingly, we have demonstrated above that HAL efficiently attenuates pAP-
induced Ca -imbalance in AD, which is in controversy with the present findings 
regarding Ca2+. Most, if not all, genes in mammalian cells are regulated by 
multiple mechanisms acting in concert to regulate their expression. As gene 
products change in response to cellular needs, it is likely that the repertoire of 
regulatory mechanisms influencing the expression of these genes also changes. It 
is likely, therefore, that HAL disrupts Ca -levels to cause apoptosis, however in 
an already disturbed setting, eg. in AD, it acts as a cytoprotective agent by 
inflaming defensive mechanisms such as inducing APP expression and level. 
Another major category of differentially regulated genes encode for cell defense 
proteins, which include anti-oxidative stress proteins and heat shock proteins. The 
majority of these transcripts were differentially expressed in HAL and RISP-
treated animals. 
Oxidative stress can occur as a result of a number of stimuli. During aerobic 
metabolism under stress, reactive oxygen species (ROS) are produced as a result 
of partial reduction of oxygen. ROS were originally considered to be detrimental 
to cells, but recently it has been shown that it is involved in redox regulation by 
adjusting cellular activities225. These ROS induce the expression of defense-
related genes such as those encoding glutathione-S-transferase (GST). In this 
study, the GST- and peroxidase enzyme-encoding genes were both up-regulated 
after treatment with HAL (Table IX/A). Glutathione acts as a redox-sensor and is 
involved in the multiple regulatory systems coordinating the expression of defense 
genes226, therefore the increasing glutathione biosynthetic capacity could enhance 
resistance to oxidative stress. Because HAL is known to be toxic to cells, up-
regulation of defense genes might be a compensatory mechanism, just as 
discussed with the induction of APP. 
- Effect on the dopaminergic system 
Antipsychotics had been assumed to suppress DA-mediated neurotransmission 
either by decreasing brain DA-levels (eg. reserpine) or by antagonizing D2-
receptors. Contrary to the hyper-dopaminergic hypothesis, some previous data 
indicate a reduced central DA output associated with SCH, a phenomenon that 
was found to correlate with negative symptoms, such as anergia, emotional 
blunting, lack of drive, etc221. Consequently, both hypo- and hyperfunctioning of 
brain DA-systems in SCH have been proposed and, tentatively, both types of 
dysfunction might even occur simultaneously, albeit in different bran regions. 
Responsiveness of both negative and positive symptoms of SCH to antipsychotics 
has been documented in clinical settings. Importantly, however, no effect on DA 
metabolism and transmission were significantly altered by HAL or RISP in our 
experiments at the genetic level. Their antipsychotic effect therefore is not by 
modifying DA turnover and bioavailability or modifying genes encoding for D2-
receptors, but by fine-tuning signal transduction pathways. By acting on 
intracellular signaling, HAL and RISP are potent inductors of neuronal plasticity. 
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As such, they are hypothesized to have an impact on remodeling pathological 
dopaminergic and glutamatergic neuronal circuits seen in SCH and other 
neuropsychiatry conditions as part of their modes of action. 
Interestingly, however, both HAL and RISP significantly altered the expression of 
endothelin. There is increasing evidence that endothelins and endothelin receptors 
play a role in brain mechanisms associated with behavior and neuroendocrine 
regulation, as well as cardiovascular control. A growing mass of data suggests that 
they may be acting as true neurotransmitters or neuromodulators. They are known 
to stimulate DA-release in the CNS228. The effects of endothelin in the brain could 
be a continuum from physiologically relevant neuromodulatory effects at low 
concentrations, through reversible hypermetabolism at higher doses, to permanent 
neurotoxic neuronal damage at very high concentrations. 
Altered expression of the endothelin-system as a result of administration of either 
of the two antipsychotics underlying these neurochemical effects do not 
necessarily have to be different. While it is clear that physiological activation of 
endothelin receptors induces a rise in intracellular Ca2+ levels229 , supra-
physiological levels of Ca2+-influx have been associated with neurotoxic 
events230. This may add to the well-known toxic effect of HAL. Alternatively, it is 
possible that the low-dose, physiological action of endothelin is mediated by a 
direct effect on dopaminergic terminals, whereas the high-dose effect also 
involves other mechanisms, such as glutamate and NO release 31. It is well-known 
that the high levels of glutamate may induce neurotoxic effects in the brain, 
further explaining the neurotoxic effect of HAL. 
Taken together, the impact of HAL and RISP on the dopaminergic system might 
be accomplished not directly, as suggested above, but via the novel neuro-
transmitter/modulator endothelin system. 
- Commonalities 
The focus of this study was the identification of genes after treatment of rats with 
HAL and RISP. Even though there was an overlap of only a few genes at 
exposure to HAL and RISP, both drugs have interfered with the same cellular 
functions. RISP acutely had an impact on more genes than HAL. This might be 
attributable to the fact that the mode of action of RISP is more diverse: it is a high 
potential D2-, 5HT2- and NA-antagonist, whereas HAL is a D2-antagonist with 
some oi-activity. Taken together, this observation suggests that antipsychotics 
with different pharacological characteristics share targets at the molecular level. 
Interestingly, some significantly enriched pathways differ after treatment with 
both drugs over time. Transcripts implicated in neuronal plasticity, survival, 
oxidative changes and metabolism in general are widely interfered with by HAL 
and RISP in our acute experiments, but these antipsychotic drugs had less diverse 
impact on these genes, or did not change chronically their expression profile 
(Tables IX-XII). This finding is well established, since high potential agents like 
HAL and RISP are thought to have more profound impact on initiating therapy. 
Chronically, however, drastic changes subside. 
Whereas conventional neurological assessment utilizes behavioral, functional, and/or 
morphological techniques to estimate overt effect of drugs, new methods are being 
developed that identify molecular changes on the gene expression level that are associated 
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with medical treatment. Based on our findings, gene expression profiling is an invaluable 
method for delineating the neuro-psycho-pharmacological actions of antipsychotics by 
simultaneuously identifying thousands of genes modulated in response to drug exposure, 
and it allows the determination of genes responsible for treatment failure or development 
of drug resistance. 
Additionally, cDNA arrays permit the measurement of early gene expression events in 
cells rather than cumulative systemic effects and, thus, may provide a means of early 
detection of therapeutic effects. Microarrays have considerable potential to define in 
molecular terms the progression of a disease and identify biochemical pathways that can be 
used as targets for future therapeutic intervention. The identification of unique gene 
expression patterns associated with cellular responses to a particular chemical or class of 
chemicals can be used in conjunction with a variety of pharmacological assessment 
platforms to identify the presence of both physiologically and medically useful substances. 
The feasibility of using DNA arrays for this assessment depends on the ability of this 
technology to identify reproducible gene expression signatures from relatively small 
quantities of RNA. 
The use of QRT-PCR in combination with the microarray work ruled out the dissociation 
of protein translation from gene transcription. Therefore, gene expression profiling can be 
a powerful tool with which to compare the mechanisms of action of different agents, which 
elicit similar biological responses. As such, our study would serve as a platform for all 
further investigation of the molecular effects of HAL and RISP in rats and humans. 
Elucidation of the metabolic and signal transduction pathways and gene transcription 
factors that underlie the pathophysiology of neuropsychiatric disorders and the actions of 
various medications could also reveal targets for the development of novel therapeutic 
agents. The continued application of major advances in molecular and cellular 
neurobiology to psychiatric problems over the coming years holds a bright future for the 
treatment, and possibly prevention, of AD and other neurometabolic disorders. 
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SUMMARY 
1. Fibroblasts and lymphocytes show biochemical differences in AD by exhibiting abnormal Ca2+ 
homeostasis. 
2. Biphasic effect of PAP may shed new light on understanding cellular alterations in dementia 
and differences between tissue-specific pathologies in the same condition. 
3. Biochemical alterations in the periphery may support the diagnosis of AD, may help 
monitoring the progression of the disease and responsiveness to treatments. 
4. HAL and RISP are potent in antagonizing pAP-induced Ca2+-imbalance. 
5. These antipsychotics are safe with respect to APP metabolism, and acute HAL (ie. pulse-
therapy) might be beneficial on APP processing in AD. 
6. A "protective cycle " of antipsychotics is proposed in AD. 
7. HAL and RISP are involved in interfering with the expression of a large array of genes 
involved in Ca" -signaling, survival and cellular plasticity. 
8. Antipsychotics with different pharmacological characteristics share targets at the molecular 
level, including CO2*-homeostasis. 
9. Ca2+ is central in the pathogenesis of AD, and agents targeting Ca2+ may slow or inhibit the 
progression of and might even reverse AD and its corollary symptoms. 
10. Co2* might be a unifying molecule in most neurodegenerative disorders and also in metabolic 
diseases afflicting extraneuronal organs. 
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